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1 INTRODUCTION 
 
1.1 Taxonomy and pathogenesis 
 
Measles virus (MV) belongs in the Mononegavirales order (group V, negative-sense 
single-stranded RNA i.e. −ssRNA) of the seven different virus orders (ICTV 2013). 
Mononegavirales has five families of which MV belongs to the paramyxoviridae family 
(‘para’ meaning ‘alongside’ and ‘myxo’ meaning ‘mucus’ from Greek and ‘virus’ 
meaning ‘venom’ from Latin). Paramyxoviridae also includes other human pathogens 
such as parainfluenza (PIV) and human respiratory syncytial virus (HRSV). Currently 
there are no specific antiviral treatment for any of these three viruses nor are there 
vaccines for PIV or HRSV. Measles belongs in the subfamily of Paramyxovirinae, in 
the Morbillivirus genus that has six species. Morbilliviruses infect primates, dogs, 
cattle, cetaceans and possibly bats (SIB, ViralZone, Morbillivirus 2011, de Vries et al. 
2015) and they can cause severe systemic disease. However, MV only have disease 
reservoirs in humans, which is one of the prerequisites for making its eradication 
possible since animals can not cause disease outbreaks in humans (Moss & Griffin 
2012). 
Measles is one of the most infectious viruses known (Strebel et al. 2013). It is 
transmitted through touch or contact with respiratory droplets from infected people or 
through the air (THL, Measles 2014). Symptoms start 10–12 days after infection and 
include high fever, runny nose, bloodshot eyes and tiny white spots inside of the mouth 
(WHO, Health topics: measles 2014). Several days later a recognizable rash starts on 
the face and spreads downwards. People with measles mostly recover by themselves 
within 2–3 weeks but measles also causes serious complications mostly in malnourished 
children. Most of the deaths happen because of secondary infections occurring during 
the immunosuppression caused by the virus (Moss & Griffin 2006) (see chapter 1.2.3. 
for more about the mechanism of immunosuppression). In industrialized countries the 
most common complications, in order of prevalence, include ear infection, diarrhea, 
pneumonia, death (0.1–0.3%), postinfectious encephalitis and subacute sclerosing 
panencephalitis (SSPE) that causes lethal progressive neurological deterioration (Moss 
& Griffin 2012, Strebel et al. 2013).  
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MV was first isolated in 1954 (Enders & Peebles 1954). The isolation of the so 
called Edmonston strain was soon followed by the development of a measles vaccine in 
1963 (Enders 1961, Katz et al. 1962, Marley 1963). The live vaccine contains viruses 
that have been attenuated by cell culture passaging. Since widespread vaccinations the 
number of measles incidences have plummeted and the World Health Organization has 
a goal to eradicate measles by 2020 from everywhere else except the Southeast Asia 
WHO region (for example India and Indonesia). This region reported most of the fatal 
measles cases (55%) in 2010 and thus the process is expected to take longer there. The 
eradication should be accomplished by improving surveillance and maintaining or 
improving the vaccination coverage. The worldwide goal was to decrease the mortality 
by 95% between the years 2000 to 2015 (Simons et al. 2012). In the year 2000 an 
estimated 535 000 people died from measles. There are no exact numbers because of 
insufficient reporting in developing countries without extensive surveillance. The World 
Health Organization has already reported a 77% reduction down to 122 000 deaths in 
2012 (WHO, Measles fact sheet 2014). It seems that the 95% reduction plan was too 
ambitious and will not be met, but no one can deny that the achievement already 
reached is impressive (WHO, Weekly Epidemiological Record 2014).  
More than 95% of the reported measles deaths occur in developing countries and 
are children under the age of five. However, there are also outbreaks in industrialized 
countries with good vaccination programs mostly because of vaccine refusals which 
temporarily lowers the herd immunity (Jansen et al. 2003, Zandotti et al. 2004). The 
herd immunity has to be as high as 95% for prevention of measles outbreaks (Moss & 
Griffin 2006). This is why measles currently poses a risk – that is often underestimated 
– to the public in industrialized countries. More so than the presently ongoing outbreak 
of Ebola virus that is also caused by a member of Mononegavirales. 
 There are yet no specific or efficient broad-spectrum antiviral treatments for 
measles. Herein, it is crucially important to determine its molecular and functional 
architecture. Usually it is treated with a broad-spectrum antiviral drug with vitamin A 
supplements to prevent complications. However there are new promising drugs in 
development e.g. BCX4430 (Warren et al. 2014) and ERDRP-0519 (Krumm et al. 
2014). Both inhibit the viral RNA polymerase and have been tested in rodents. 
BCX4430 is a broad-spectrum antiviral drug terminating RNA chain formation as a 
nucleoside analogue (Warren et al. 2014). ERDRP-0519 also targets the RNA 
polymerase, but with a lead compound and it is specific to morbilliviruses (Krumm et 
al. 2014). ERDRP-0519 is more potent candidate for measles because of its efficiency. 
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 MV also shows promise in oncolytic virotherapy because it targets cancer cells 
through the nectin-4 receptor (Noyce et al. 2011). Paramyxoviruses are appealing as 
viral vectors in general because they are free of icosahedral capsid symmetry constraints 
and have two different proteins on their envelope that mediate recognition and fusion 
for easier retargeting (Cattaneo 2010). Understanding MV structure and the signalling 
of its proteins will give valuable information to the battle against virus diseases and also 
for the biotherapeutic usage of paramyxovirus vectors. 
 
1.2 Structure and assembly 
 
MV is an enveloped pleomorphic virus, which means that virions i.e. virus particles 
look different in shape and size (Liljeroos et al. 2011). In the wild type virus, the size 
ranges from 50 to 510 nm. It has a linear nonsegmented –ssRNA genome that is packed 
inside a helical nucleoprotein capsid (Moss & Griffin 2006). The 16 kb nucleotide 
genome has six genes that code for eight proteins: nucleoprotein (N), phosphoprotein 
(P), virulence factors C and V, matrix (M), fusion (F), hemagglutinin (H) and large (L) 
protein (Figure 1). C and V are nonstructural proteins and are expressed from the P 
gene. C is expressed by alternative initiation codon and is much smaller than P as is 
seen in Figure 1. V is also smaller than P and is expressed by mRNA editing: 
pseudotemplated insertion of one or sometimes three G nucleotides at position 753 
resulting in protein with the same N-terminal region and a different cysteine rich, zinc 
finger-like C-terminal region (Cattaneo et al. 1989). Both P and V mRNA are produced 
in similar quantities. A schematic diagram of the MV structure is presented in Figure 2.  
 
 
 
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Figure 1. Measles genome reproduced and modified with permission from 
(viralzone.expasy.org, SIB Swiss Institute of Bioinformatics). The genome has six 
genes that code for eight proteins: nucleoprotein (N), phosphoprotein (P), C, V, matrix 
(M), fusion (F), hemagglutinin (H) and large (L) protein. C is produced from the P gene 
by so called leaky scanning of the polymerase resulting in a different starting codon. V 
is produced from the same start codon than P, but mRNA editing changes its reading 
frame in the C-terminal region. 
 
 
 
 
Figure 2. MV structure reproduced and modified with permission from (Liljeroos et al. 
2011). 
 
 
1.2.1 Attachment and viral entry 
 
The life cycle of a virus starts with a virus entering a host cell. As seen in Figure 2, the 
viral membrane of the MV contains H and F glycoproteins. They work together in viral 
entry in to the host cell (Moss & Griffin 2006). H recognizes the potential host cell and 
attaches to a receptor in its membrane. H in a wild type virus binds primarily to 
signalling lymphocyte activation molecule (SLAM) i.e. CD150 in host cell membranes 
(Tatsuo et al. 2000) and in the Edmonston vaccine strain to both SLAM and membrane 
cofactor protein (MCP) i.e. CD46 (Naniche et al. 1993, Schneider et al. 2002, Moss & 
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Griffin 2006). CD46 receptor is present on all nucleated cells, whereas SLAM is present 
only in activated B and T lymphocytes and antigen-presenting cells (dendritic cells and 
macrophages). H also binds to nectin-4 in epithelial cells of the respiratory tract, as 
found more recently, which makes the virus transmissible after circulation in the body 
(Mühlebach et al. 2011). The infection cycle in a host body is depicted in Figure 3. 
After attachment of the virus, the infection cycle of the cell continues by a 
conformational change of H, which allows the activation of the other glycoprotein F 
(Brindley et al. 2013, Jardetzky & Lamb 2014). F then also goes through a 
conformational change that mediates fusion of the virion with the host cell membrane 
and so the viral RNA is released to the host cytoplasm.  
 
 
 
Figure 3. MV infection cycle reproduced and modified with permission from 
(Immunopediae.org 2010). 
 
 
1.2.2 Viral replication and transcription 
 
In the host cell cytoplasm, viral RNA is transcribed and translated to viral proteins and 
later in the viral life cycle preferably just replicated (Plumet et al. 2005). The genes are 
transcribed in fashion of polarized attenuation, where the polymerase sometimes 
dissociates in between reading the genes at an intergenic junction leading to a polarized 
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mixture of mRNA (Ray & Fujinami 1987, Plumet et al. 2005). The polarized mixture 
contains different amounts of each transcribed gene, where the first gene is transcribed 
the most abundantly and the last gene is transcribed the least abundantly and so on. The 
RNA genome is coated with N protein; NCORE domain (Figure 4) is responsible for 
forming the ribonucleocapsid (RNP) where N self-assembles in to a helical capsid 
coating the viral RNA genome (Karlin et al. 2002a) (Figure 5A).  
P protein however has two main functions. The first is to work as a chaperone 
(Figure 5A and B). P keeps the newly synthesized N0 (N without RNA) from 
assembling around the host RNA; P N-terminal (PNT) domain (Figure 4) binds to 
N0CORE and P C-terminal (PCT) domain binds to N0TAIL and keeps N0 from self-
assembling around the wrong RNA (Curran et al. 1995a, Chen et al. 2003). P also 
retains N in the cytoplasm (Huber et al. 1991). N alone would localize to nucleus. 
Secondly, P also works as a tetramer (Communie et al. 2013a) binding to RNP 
(Figure 5B) (Karlin et al. 2003). In this second function, it is believed to cartwheel 
along the RNP (Tarbouriech et al. 2000) organizing the loose NTAIL structures and 
tethering the RNA-dependent RNA-polymerase (RdRp) to the genome and so 
stabilizing the polymerase–genome interaction (Krumm et al. 2013). PNT and NTAIL 
domains are structurally disordered adapting secondary structure only when induced by 
binding to another protein (Karlin et al. 2002b, Bourhis et al. 2006). Structural disorder 
is believed to be beneficial because it enables binding with multiple different proteins. 
And as support for this NTAIL does have multiple binding partners in the host cell as told 
in more detail in chapter 1.2.3 (p. 16). 
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Figure 4. A) P and B) N structure and binding sites reproduced and modified with 
permission from (Bourhis et al. 2006).  
 
 
L protein is a polymerase that replicates viral RNA even without the disassembly of the 
RNP structure. This is possible by the help of P working as a cofactor and helping the 
polymerase to access the N protein protected genome (Figure 5A) (Bourhis et al. 2006, 
Leyrat et al. 2011). The polymerase binding site in P has not been verified for MV, 
except that it is somewhere in PCT domain (Chen et al. 2003). Together they form the 
hetero-oligomeric RdRp complex. The newly replicated genome is immediately 
encapsidated by N where the P-N0 encapsidation complex is used as a substrate 
(Figure 5A). The N0 is readily attached to RNP because the N-RNA complex is thought 
to be more stable than P-N0 complex (Leyrat et al. 2011). P and L also work together to 
transcribe the viral RNA (Sun et al. 2011) (Figure 6). L has all the polymerase enzyme 
functions needed for initiation, elongation and termination of RNA synthesis and adding 
the 5’-cap and 3’-poly(A) tail. The binding site of the polymerase differs in 
paramyxoviruses, but as said in MV the PCT domain recruits the transcriptional 
machinery by binding to RNP and L (Bourhis et al. 2006). Only PCT is required for 
transcription (Karlin et al. 2002b) as opposed to replication where PNT is required for 
encapsidation of the new genome. It has been suggested that P or P-L complex binds to 
NTAIL, but the interaction is weak in order for the P-L complex to be able to move along 
the RNP (Kingston et al. 2004b).  
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Figure 5. The first function of P: A) P (denoted as blue) in an N-P-L complex (N 
denoted as red, L and RNA denoted as green) in replication: 1: P and L working 
together in P-L complex 2: P brings N0 for new RNP in the replication site, P attaches to 
NTAIL in RNP, 3: N0 is given to newly constructed RNP as PX domain attaches to NTAIL 
in RNP rather than N0TAIL. PMD is the polymerization domain. B) P binding to N. 
Reproduced and modified with permission from Bourhis et al. 2006. 
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Figure 6. The second function of P in transcription: P (denoted as purple) in complex 
with L (denoted as grey) in transcription. Reproduced and modified with permission 
from viralzone.expasy.org, SIB Swiss Institute of Bioinformatics. 
 
 
1.2.3 Interaction with host proteins and immunosuppression 
 
Efficient viral RNA synthesis requires host proteins (Moyer et al. 1990). Virus needs 
cellular enzymes, but also other virus–host interactions are important and some of them 
have already been discovered. For example, cytoskeletal proteins like tubulin is 
believed to provide a physical anchor for the viral RNA synthesis (Moyer et al. 1990, 
Berghäll et al. 2004). The role of actin is under an ongoing research. Actin is needed to 
help in the virus release out of the host cell probably by helping the virus to protrude 
outwards from the cell (Moyer et al. 1990, Berghäll et al. 2004, Dietzel et al. 2013). 
Also, M-RNP complex is delivered to cell surface along actin filaments (Wakimoto et 
al. 2013, Dietzel et al. 2013). Actin indirectly regulates glycoprotein mediated cell-to-
cell fusion by binding to M (more about cell-to-cell fusion in chapter 1.2.4, p. 18). N 
protein increases viral replication and transcription by binding to cellular heat shock 
protein Hsp72 and Peroxiredoxin 1 (Prdx1) (Zhang et al. 2005, Watanabe et al. 2011). 
They both inhibit P binding to NTAIL by competitive inhibition and possibly increase the 
speed the RdRp complex travels along the RNP because the interaction of P and NTAILS 
are less frequent.  
MV also interferes with the immune system of the host with mostly the help of its V 
protein, but also C and P proteins. V protein binds and blocks host proteins from acting 
for eradication of the virus infection; V protein, and also C and P indirectly, prevent 
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interferon (IFN) production, which is essential for normal immune response. IFN is an 
infected cell’s way to communicate to nearby cells to promote their antiviral defences. 
V protein binds, at least, to DexD/H-box helicases called a melanoma differentiation-
associated protein 5 (MDA5) and a Laboratory of genetics and physiology protein 2 
(LGP2) and blocks their sensor activity for recognizing viral RNAs and thereof by 
blocking also consequently IFN production (Nakatsu et al. 2008, Childs et al. 2012). V 
works also as a decoy for IB kinase  (IKK) and prevents the phosphorylation of its 
substrate IFN regulatory factor 7 (IRF7) which is needed again for IFN production 
(Pfaller & Conzelmann 2008). V also binds to p65 subunit of nuclear factor of the  
light chain enhancer of B cells (NF-B) and prevents its nuclear localization and 
function as a transcription factor for enhancing IFN production (Schuhmann et al. 
2011). Also P and C inhibit NF-B to a lesser extent, but with different unknown 
mechanism. Furthermore, V also inhibits JAK/STAT signal transduction cascade 
needed for IFN production by inhibiting signal transducers and activation of 
transcription (STAT) proteins (Devaux et al. 2007). Likewise P does this, but in smaller 
scale as V. On the other hand, the importance of C protein remains to be elucidated, but 
it (and possibly V also) has been suggested to downregulate the transcription of viral 
genes to an optimal level that allows virus production, but minimises IFN production so 
that the host cell does not die too quickly (Witko et al. 2006, Nakatsu et al. 2008). 
Herein, the P gene products interfere with the immune system in many ways. Possibly 
this mainly V-induced change in lymphocyte signalling together with lymphopenia (loss 
of lymphocytes and formation of syncytia i.e. virus spread through cell-to-cell fusion 
and less lymphocytes circulating in blood), cause the long immunosuppression in 
patients, unique to MV infection among the paramyxoviruses (Pfaller & Conzelmann 
2008). 
 
1.2.4 Viral release from the host cell 
 
Finally, the M protein is especially important at the end of the virus life cycle. As 
recently reported, it primarily coats the RNP that contains the genome of the virus, 
although some of it directly underlines the viral membrane (Figure 2) (Liljeroos et al. 
2011). Its importance is also highlighted in the fact that mutated M protein defective in 
binding N causes inefficient virus production and lingering infection in SSPE (Hirano et 
al. 1993). M is believed to transport the RNP to the virus release site along actin fibers, 
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working as a so-called assembly organizer, bringing the genome together with the 
envelope of the virus (Dietzel et al. 2013). In some other paramyxoviruses M protein 
binds directly to actin (Giuffre et al. 1982), but it seems that in measles probably a 
myosin – a motor protein that transports cargo along actin fibers – transports the 
M-RNP complex inside a Rab11A-positive recycling endosomes (REs) to the cell 
membrane (Nakatsu et al. 2013). When M-RNP complex reaches the host cell 
membrane, it groups efficiently to lipid rafts (Vincent et al. 2000, Manié et al. 2000). 
Lipid rafts are cell membrane domains enriched in certain proteins and lipids 
(cholesterol and sphingolipids). They are sites where MV preferably pinches off from 
the host cell. Also glycoprotein F groups independently to lipid rafts and enhances the 
enrichment of M in those sites (Vincent et al. 2000, Pohl et al. 2007). F associates with 
the other glycoprotein H bringing it to the release site (Vincent et al. 2000). M then 
interacts with F and H (Cathomen et al. 1998a, Wakimoto et al. 2013) and herein all the 
viral components have concentrated to the release site. And finally, the virion pinches 
off from the cell and the RNP is enveloped – in a yet unclear mechanism – with a host-
derived membrane that is enriched with viral F and H glycoproteins (Salditt et al. 2010).  
MV is released from the apical side of the polarized epithelial cells (Blau & 
Compans 1995, Sinn et al. 2002, Nakatsu et al. 2013). In the host body, the initial site 
of the infection is respiratory system and the epithelial cells lining the cavities of the 
respiratory tract. Once inside the cells, the virus needs to be released to the right side of 
the respiratory epithelia to produce enough virions to infect other hosts through 
coughing etc. The M-RNP complex is delivered to the apical side by Rab11A-positive 
REs along the actin fiber network that is highly concentrated in the apical side of 
epithelial cells (Naim et al. 2000, Riedl et al. 2002, Liljeroos et al. 2011, Nakatsu et al. 
2013). M-RNP then directs the remaining viral components - the glycoproteins - to the 
apical side also and determines the so called polarity of the virus release. Though the 
virus is released mainly from the apical surface, it is suspected to infect neighbouring 
epithelial cells and underlying tissues by cell-to-cell fusion directed by the 
glycoproteins F and H (Moll et al. 2001). The glycoproteins have basolateral sorting 
signals that direct them away from apical side in increasing amounts during virus life 
cycle (at least in cell culture) (Naim et al. 2000). So new viruses are at first probably 
released mostly from the apical side to the lumen of the respiratory tracts and later they 
spread more and more to neighbouring cells through local cell-to-cell fusion. 
Eventually, the virus ends up in white blood cells that are trying to clear up the infection 
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by engulfing infected cells. The virus then hitchhikes a ride spreading throughout the 
reticuloendothelial system creating systemic infection and viremia (see Figure 3).  
Differences in the release of viral particles among paramyxoviruses might be the 
leading reason for the high infectivity for MV. For example HRSV and Sendai virus M 
protein does not associate lipid rafts individually without the glycoproteins (Harrison et 
al. 2010) and also the polarized release system for MV allows efficient spreading 
through the respiratory system and later systemic infection through the basolateral 
sorting signals of the glycoproteins. Also the immune system suppression plays an 
important role in this.  
 
1.3 Phosphorylation in measles proteins 
 
Phosphorylation is one of the post-translational modifications in proteins. It can be done 
in three measles protein residues: serine, threonine or tyrosine. There are many possible 
phosphorylation sites in the measles proteins – the sites in the protein constructs that I 
used are shown in Appendix 1. Phosphorylation is done by kinase enzymes and 
dephosphorylation by phosphatase enzymes. Phosphorylation of virus proteins often 
plays a role in signalling with the host cell and can benefit the virus life cycle. MV is no 
exception to this. In fact, a novel strategy to control measles infection could be to target 
host kinases. The Akt serine/threonine kinase, also known as protein kinase B (PKB), 
has been shown to be important for virulence in many paramyxoviruses and inhibiting 
its function reduces measles replication (Sun et al. 2008). Herein, Akt inhibitor drugs 
could also work as broad-spectrum antivirals. They are already under vast research for 
cancer therapy and herein, it would be easier to bring them to use also as antivirals.  
P is heavily phosphorylated with PNT domain containing most of the 
phosphorylation sites (Karlin et al. 2002b). It also binds to N0 protein with that 
terminus, but their binding together is not due to a phosphorylation since chaperone 
activities work also in Escherichia coli (E. coli) bacteria (Kingston et al. 2004b, 
Liljeroos, L. & Butcher, S.J., personal communication). Unphosphorylated P also 
oligomerizes (Communie et al. 2013b) and N forms helices in E. coli (Liljeroos, L. 
& Butcher, S.J., personal communication) so these actions are not due to a 
phosphorylation modification – at least not in a critical way. Phosphorylation 
modifications are not vital to these functions, but have more complex purposes in virus 
infection.  
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The phosphorylation of P protein in MV has been hypothesized to work as a switch 
between replication of viral genome and transcription of viral mRNA. PNT is 
phosphorylated by cellular casein kinase 2 (CK2) at least in serine residues S86, S151 
and S180 (Das et al. 1995). Phosphorylation in S86 and S151 downregulates viral 
transcription (Sugai et al. 2012). Then again virus infection seems to activate Akt which 
directly or indirectly phosphorylate P and leads to favouring of transcription over 
replication (Sun et al. 2008). Therefore, different phosphorylation patterns of P seems to 
lead in favouring of replication or transcription over the other and they might be 
achieved by different kinases. In addition of phosphorylation, also accumulation of N0-P 
complex has been speculated to increase viral replication over transcription (Howard & 
Wertz 1989, Plumet et al. 2005). 
More evidence of this comes from other paramyxoviruses. It has been reported, for 
example, that phosphorylation of threonine residue T286 of P increases mRNA 
transcription in parainfluenza virus 5 (PIV5) (Sun et al. 2011). But it has been also 
shown that phosphorylation of PIV5 P S308 reduces gene expression and prevents 
cytokine induction, which might benefit the virus in long term by keeping the host cells 
in better condition (Sun et al. 2009). This happens by Polo-like kinase 1 (PLK1) which 
is also a serine/threonine kinase that plays a role in regulating the cell cycle. It binds to 
S157 and phosphorylates S308. It is also likely that different paramyxoviruses use 
different host kinases. Also phosphorylation of S157 reduces gene expression, but it is 
not clear if this happens due to phosphorylation in P, V or both since they are 
homologous in the N-terminus. All strains do not have this phosphorylation site so it 
might contribute to different virulence in different strains. Also, mumps virus 
phosphorylation of recombinant P amino acid residue T101 has been reported to 
decrease RNA transcription (Pickar et al. 2014). Hence, it may be that phosphorylation 
of P and V regulates viral gene expression in the course of the paramyxovirus virus life 
cycle. It was hypothesized that phosphorylation of P might change its ability to bind 
RNA or to interact with a yet not identified host protein. It seems that phosphorylation 
of PNT domain serine or threonine residues usually increases replication over 
transcription. 
In measles N phosphorylation sites S479 and S510 are reported to be 
phosphorylated in the C-terminal tail region as also sites S425, T477, S481, S482 and 
S505 depending on the viral strain (Hagiwara et al. 2008, Prodhomme et al. 2010). 
Their popularity in different wild type or vaccine strains varies, but the major 
phosphorylation sites S479 and S510 are almost always phosphorylated. Herein, 
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different phosphorylation patterns allegedly influence the attenuation of the strains. The 
sites are phosphorylated most likely also by CK2 (Prodhomme et al. 2010). N binds to P 
with residues 488–499 (Bourhis et al. 2004) so only the flanking areas have 
phosphorylation. It seems that P and N are mostly phosphorylated in their structurally 
disordered regions so phosphorylation probably fine tunes interactions of the viral 
proteins with each other and cellular proteins. As more evidence of this, the N 
phosphorylation state does not regulate its nuclear trafficking, N-P or N-M interactions 
critically, but the binding of P and N reduces phosphorylation of P (Sugai et al. 2012) 
and N (Sugai et al. 2013). It has been suggested to increase the stability of viral RNA. 
Sugai et al. suggested that phosphorylation of N decreases viral gene expression in the 
early phase of the viral life cycle to minimize cytokine induction in the critical first 
stages of infection. And later it prevents the excessive phosphorylation of P and 
decreases viral transcription and replication (Sugai et al. 2012). 
It has been reported that phosphorylation of N is on serine and threonine residues in 
RNP-associated N, but only in serine in the free form of N that was not associated with 
the transcription machinery (Gombart et al. 1995, Prodhomme et al. 2010). This can 
mean that T477 is critical for nucleocapsid assembly. Also, there were no tyrosine 
phosphorylation. It has been linked to persistent neuroblastoma infections (Segev et al. 
1995). Herein, it is possible that tyrosine phosphorylation is important for SSPE strains 
and possibly N to M binding since this is disrupted in SSPE (M binding happens in this 
region of N) (Hirano et al. 1993). So it seems that phosphorylation of N has similar 
effects than phosphorylation of P: regulating gene expression to a suitable level which 
varies in the course of the infection cycle and the differences in phosphorylation 
patterns might change the severity of the disease caused by different strains. 
 M protein phosphorylation has also been reported (Fujinami & Oldstone 1979). 
 
1.4 Phosphate affinity electrophoresis as a method for studying 
phosphorylation 
 
Phosphorylation is usually studied by mass spectrometry (Karlin et al. 2002b), 
radiolabelling with 32P (Vidal et al. 1988) or by using antibodies for different 
phosphorylated amino acids. Radiolabelling and the use of antibodies are most suitable 
when the sample is homogeneous and only one site is phosphorylated. Recently, 
alternative methods have been introduced for determining phosphorylation status of 
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proteins. There is, for example, a stain for phosphorylated proteins in SDS-PAGE gel 
that recognizes all the three possibly phosphorylated amino acid residues (Life 
TechnologiesTM, Pro-Q® diamond phosphoprotein gel stain 2014). However, it does not 
separate different isoforms of phosphorylated proteins, where a protein has varying 
amount of phosphorylated protein residues in the sample. The phosphate affinity 
electrophoresis does this. 
The phosphate affinity electrophoresis method uses Phos-tagTM phosphate-binding 
molecules to bind to phosphorylated amino acid residues in proteins. Phos-tagTM 
molecules were first discovered in 2002 at Hiroshima University. Now there are four 
different kinds of kits available that uses the Phos-tagTM molecule: acrylamide, agarose, 
biotin, and mass analytical kit (Wako Pure Chemical Industries, Ltd). Phos-tagTM 
electrophoresis uses acrylamide-bound Phos-tagTM molecules (Figure 7) that bind 
reversibly to phosphate groups in proteins and retard their running in electrophoresis 
when compared to unphosphorylated ones. There are many advantages in Phos-tagTM 
electrophoresis: it is non-radioactive, non-denaturing so it allows downstream 
applications such as mass spectrometry and that it recognizes all phosphorylated sites 
without having to use three different antibodies for phosphorylated serine, threonine and 
tyrosine separately. Phos-tagTM electrophoresis also recognizes different isoforms of 
phosphorylated proteins and thus it is possible to follow the time course of the 
phosphorylation. Another advantage is that one can determine different isoform ratios 
from the sample. A disadvantage is that the method does not identify the 
phosphorylation site unless it is coupled with mass spectrometry.  
 
 
 
Figure 7. Acrylamide-pendant Phos-tagTM ligand and its reversible binding to 
phosphomonoester dianion (ROPO32-) by Mn2+ –Phos-tagTM (M2+ = Mn2+) (Kinoshita et 
al. 2006). 
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2 RESEARCH OBJECTIVE 
 
The purpose of this thesis was to produce phosphorylated versions of the MV proteins: 
P, N and M. The phosphorylation status was determined in the proteins individually and 
also in the P-N complex. The phosphorylation status of recombinant proteins produced 
in bacterial or mammalian cells was compared to the viral proteins. The differences 
between the phosphorylation modifications of cellular and released virus were 
compared. The results could possibly shed more light to what roles phosphorylation of 
these proteins play in the virus life cycle. 
 
3 MATERIALS AND METHODS 
 
3.1 Cloning 
 
New England BioLabs’ NEBcutter tool confirmed that there are no NotI or EcoRI 
restriction enzyme sites in the middle of the P gene (see Appendix 2 for links of the 
sites used) and primers were planned accordingly. Primers P-Forward-His-NotI and 
P1-48-Reverse-EcoRI were used for cloning truncated version of the P gene that 
expresses amino acids 1–48 out of 507 (primers are listed in Table 1). Same forward 
primer and P-Reverse-EcoRI were used for the whole protein. P1-48 in a pET41(a)-
vector and P in a pTT5SH8Q2-vector (both kindly provided by Liljeroos, L.) were used 
as templates (Liljeroos, L. and Butcher, S.J., personal communication). Composition of 
the plasmid is presented in Appendix 3. P was cloned again to pTT5SH8Q2-plasmid to 
get the His-tag at the N-terminus as in truncated P1-48. I amplified a P1-48 gene and a 
whole P gene with polymerase chain reaction. The PCR program used is in Appendix 4. 
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Table 1. Primers. 
 
Name Sequence 
P-Forward-His-NotI 5’-AATGCGGCCGCACCATGGAACATCATCATCATCAT
CATGCAGAAGAGCAGGCACG-3’  
P1-48-Reverse-EcoRI 5’-GGGGGGG GAATTCTTAGGCTCGCTCCTGTCCTG -3’  
P-Reverse-EcoRI 
(provided by 
Liljeroos, L.) 
5’-GGGGGGGGAATTCCTACTTCATTATTATCTTCATCA
GCATCTGG-3’ 
P-Forward-NotI 
(provided by 
Liljeroos, L.) 
5’-AATGCGGCCGCCATGGGCAGCAGCCATCATC 
Restriction enzyme sites are underlined 
 
 
The amplified DNA products were run electrophoretically in 0.8% (w/v) low 
electroendosmosis agarose (Supplied by BioNordika, manufactured in EU) with 120 V 
for 20 min in 1 × TAE buffer: 40 mM Tris, 20 mM acetic acid, and 1 mM 
ethylenediaminetetraacetic acid (EDTA), pH 8.0. Amplified products were purified 
from the agarose gel with PCR-purification kit (Roche). Restriction enzyme digestion 
was done separately to 425 ng of P1-48 gene and 505 ng of P gene with 286 U/ml NotI 
and EcoRI restriction enzymes for 2 h 50 min at 37°C. The pTT5SH8Q2-vector was 
purified with a Qiagen’s midiprep kit according to manufacturer’s instructions and 
3.3 µg was digested with 340 U/ml NotI and EcoRI restriction enzymes 2 h 40 min at 
37°C. NEBuffer 4 and BSA were used in restriction enzyme digestions according to 
NEB’s Double digest finder’s suggestions (link in Appendix 2). The small overhang 
DNA fragments cleaved in the reaction were removed from the restriction enzyme 
digestion products with PCR-purification kit (Roche). Ligation was done separately to 
31 ng of P1-48 gene and 19 ng of P gene with 100 ng of restriction enzyme digested 
pTT5SH8Q2-vector using 10 000 U/ml T4 DNA ligase (NEB) and incubated for 10 min 
at room temperature. One fourth of the volume of the ligation reaction mixes were 
transformed into DH5 strain of CaCl2 competent E. coli by mixing the constructs with 
bacteria and keeping them on ice for 20 minutes, giving a heat shock for a minute at 
42°C and incubating on ice for a minute. As controls 1 ng of ligated vector without 
insert and the 25 ng of restriction enzyme digested vector were transformed. 
Transformed bacteria were plated on Luria (L) culture plates with ampicillin (100 
µg/µl) as the selection factor. Untransformed DH5 were also plated onto L-plates for 
transfection efficiency determination. All the plates were incubated at 37°C overnight.  
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Ten colonies were inoculated separately from culture plates of P1-48/pTT5SH8Q2 
and P/pTT5SH8Q2 in DH5 to 3 ml of L media with 100 µg/µl ampicillin and grown 
3 h 30 min at 37°C 220 rpm. From those subclone cultures colony-PCR were done with 
same primers as previously (Table 1, p. 24) and 1 µl of culture was used as a template. 
The PCR program used is in Appendix 4. Positive subclones according to 
electrophoresis were confirmed by restriction digestion analysis as follows: Plasmids 
from 2 ml of saturated cultures were purified with Thermo Scientific GeneJET plasmid 
miniprep kit according to the manufacturer’s instructions. After purification, 3 µg of 
plasmids were digested with 333 U/ml NotI and EcoRI restriction enzymes 1 h 30 min 
at 37°C and results analysed with agarose gel electrophoresis. Plasmids from two 
subclones of P1-48/pTT5SH8Q2 and P/pTT5SH8Q2 were sent for sequencing with 
primers P-Forward-NotI and P-Reverse-EcoRI (both provided by Liljeroos, L., Table 1, 
p. 24). P1-48 was sequenced with only forward primer and P with both forward and 
reverse primers. 
The provided sequences were analysed by Blast (National Center for Biotechnology 
Information (NCBI)) and LALIGN (ExPASy, SIB Bioinformatics Resource Portal). The 
sequences were translated by Translation tool and compared with ClustalW to P gene of 
MV Edmonston strain (GenBank code: GU327676.1) and to Helsinki strain sequences 
(Liljeroos et al. 2011). Links to all sites are in Appendix 2. 
 
3.2 Protein overexpression in HEK293EBNA1 tissue culture 
 
Subclones 8 from both P1-48/pTT5SH8Q2 and P/pTT5SH8Q2 in DH5 were cultivated 
in quantity of 2 ml in L media with 100 µg/µl ampicillin 8 h at 37°C 220 rpm. The 
cultures were then diluted 1:500 to 50 ml and grown 16 h in similar conditions. The 
plasmids were purified from the cultures with a Qiagen’s midipreparation kit. Also 
other plasmids (kindly provided by Liljeroos, L.) were transformed and produced 
similarly. All of them are listed in Table 2 with concentrations and purity measured by 
NanoDrop. 
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Table 2. All the constructs used in the work and their concentrations and purity. 
DNA construct Concentration 
(ng/µl)* 
Purity, 
A260/A280* 
YFP/pTT5SH8Q2 535.3 1.91 
pTT5SH8Q2-vector 481.1 1.91 
P1-48(His-tag in N-terminus)/pTT5SH8Q2 299.8  1.92 
P(His-tag in N-terminus)/pTT5SH8Q2 346.4  1.92 
N(His-tag in C-terminus)/pTT5SH8Q2 394.5 1.92 
N/pTT5SH8Q2 383.0 1.91 
M/pTT5SH8Q2 265.6 1.92 
*Concentration and purity measured by NanoDrop 
 
 
Human Embryonic Kidney cell line 293EBNA1 (HEK293EBNA1), where EBNA1 
stands for Epstein-Barr virus nuclear antigen 1, was used for protein expression. The 
cells were always cultured at 37°C and 5% CO2 in a humidified incubator with 
Dulbecco’s Modified Eagle’s medium (DMEM), pH 7.4 with 10% (v/v) foetal calf 
serum (inactivated at 54°C for 30 min with mixing to inactivate the complement), 1 mM 
sodium pyruvate, 1 × MEM non-essential amino acids, 100 U penicillin and 0.1 mg/ml 
streptomycin. Media was always at room temperature when added to cells. The cells 
were passaged four times before transfection in order to let them recover from the 
thawing procedure.  
Polyethylenimine (PEI) transfection method was used. Transfection conditions 
were optimised with 3 ml of media in 3.5 cm cluster plates as follows: At first 300 µl 
serum and other additive –free media and 3µg of YFP/pTT5SH8Q2 gene construct as 
the transfected DNA (YFP is a yellow fluorescent protein) was incubated at room 
temperature for 5–10 min for assuring complete mixing. Different amounts of PEI were 
added for screening the best amount, mixed well by shaking the tube and incubated 10–
20 min at room temperature (in Table 3 are the used DNA to PEI ratios). As a control, 
mock transfected cells were treated without DNA and just PEI was added. The 
HEK293EBNA1 cells were washed with room temperature phosphate-buffered saline 
(PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM disodium hydrogen phosphate (Na2HPO4) 
and 1.8 mM monopotassium phosphate  (KH2PO4)), finally mixed with DNA-PEI mixes 
or just PEI and 2.7 ml culture media and incubated 24 h. The cells were 80% confluent 
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when transfected. The best DNA to PEI ratio was assessed by fluorescence microscopy 
and used when transfecting cells afterwards. 
 
 
Table 3. Transfection optimization: DNA to PEI ratios in a 6-well cluster plate. 
1:1 1:2.5 1:3 
1:4 1:5 15 µg PEI as a control 
 
 
After optimization 70–80% confluent, HEK293EBNA1 cells were transfected 
separately with 10 µg of the constructs in Table 2 (p. 26) – except pTT5SH8Q2-vector 
alone. In addition, following constructs were transfected to make protein complexes: P1-
48 (His-tag in N-terminus) and N (without His-tag) together and also P (His-tag in N-
terminus) and N (without His-tag) together. YFP/pTT5SH8Q2 were used again as a 
control for the determination of the transfection efficiency. Transfection was allowed to 
continue 48 h (24 h longer than in optimization) to get a better protein yield. The cells 
were 70% confluent when harvested at a passage number 22. 
Second transfection was done to check the results and corrected DNA amount in 
complexes to be altogether 10 µg and not 10 µg of every construct. The cells were 70–
90% confluent depending on different plate when transfected. Protein production was 
allowed to continue 49 h. The cells were 100% confluent at a passage number 28 when 
harvested. The cell cultures were tested for mycoplasma contamination by using 
PromoKine’s PCR Mycoplasma test kit II as should be done routinely for these cells. 
 
3.3 Protein purification from HEK293EBNA1 cells 
 
The transfected HEK293EBNA1 cells were washed two times with ice cold PBS and 
lysed with ice cold cell lysis buffer (1 ml per 100 mm culture dish) containing: 0.5% 
(v/v) Triton-X and 20 mM imidazole, protease inhibitors (EDTA free tablets, 1 tablet / 
10 ml solution, Roche) and phosphatase inhibitors (phosSTOP 1 tablet / 10 ml solution, 
Roche) in PBS, pH 8.3 (filtered with pore size 0.2 µm). The first batch of transfectant 
cell lysates were frozen at − 80°C overnight. The second batch were just incubated 
30 min on ice in the cold room with shaking the tubes a few times during the incubation. 
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Unphosphorylated P protein from E. coli (kindly provided by Liljeroos, L.) was added 
to the YFP cell lysate as a phosphorylation control. 
The cell lysates were centrifuged 13 000 rpm 5 min at + 4°C in cold room on a 
tabletop centrifuge. The supernatant was saved as a cytosolic fraction. Nuclei was lysed 
from the cell debris pellet with modified radioimmunoprecipitation assay (RIPA) buffer 
(1 ml per pellet) containing: 150 mM NaCl, 0.5% (v/v) Triton-X 100, 1.0% (w/v) 
sodium deoxycholate, 0.1% (w/v) SDS in 25 mM, protease inhibitors (EDTA free 
tablets, 1 tablet / 10 ml solution, Roche) and phosphatase inhibitors (phosSTOP 1 tablet 
/ 10 ml solution, Roche) in Tris-HCl, pH 7.7 (0.2 µm filtered). The lysis of the nuclei 
was allowed to continue 30 min on ice in the cold room with shaking the tubes a few 
times and nuclear fraction were collected by centrifuging 13 000 rpm 5 min in the cold 
room on a tabletop centrifuge and saving the supernatant.  
Ni2+-affinity chromatography was used for purification since Ni2+-beads (IMAC 
SepharoseTM 6 Fast Flow, GE Healthcare) bind the His-tags in the proteins. Ni2+-beads 
were prepared by washing beads with MQ water three times, adding 0.1 M nickel 
sulphate solution two times the volume of the beads and washing with MQ six times. 
Centrifuging was always done under 500 g 1 min and the Ni2+-beads where stored in 
20% (v/v) ethanol and washed three times with MQ before use.  
M protein was only divided to cytosolic and nuclear fractions as explained above, 
but P1-48, P, N, P1-48+N and P+N complex and also YFP + bacterial P control were 
further purified with Ni2+-affinity chromatography from cytosolic and nuclear fractions: 
50 µl of 50% (v/v) bead slurry were added per sample tube. The nickel beads were 
allowed to bind to proteins for 30 min in the cold room with agitation and let to settle on 
their own or centrifuged lightly before wash fractions were collected. The beads were 
then washed two times with the lysis buffer in PBS and once with buffer without 
inhibitors to avoid them from showing in electrophoresis gels later. The beads were 
always washed with 200 µl of buffer per tube. After removing the last wash fraction 
SDS-PAGE loading buffer (0.083 M Tris-HCl, pH 6.8, 3% (w/v) SDS, 10% (v/v) 
glycerol, 0.007% (w/v) bromophenol blue at final concentration) was added to the beads 
and to samples of wash fractions, boiled 6 min in 95–97°C and stored in − 20°C. All the 
remaining wash fractions were frozen with liquid nitrogen and stored at − 80°C.  
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3.4 Virus production in Vero/SLAM tissue culture 
 
Vero/SLAM cells (kindly provided by Liljeroos, L. (Liljeroos et al. 2011)) derived from 
kidney cells of African green monkey, were cultured with media containing: DMEM 
high glucose, HEPES modification (4.5 g/L glucose, L-glutamine, and 25 mM HEPES), 
3.7 g/l sodium bicarbonate, 2.0 g/l sodium chloride, 7.5% (v/v) foetal bovine serum, 
10 000 U penicillin, 10 mg/ml streptomycin and 200 µg/ml geneticin, pH 7.3. Wild type 
Helsinki strain MV (kindly provided by Liljeroos, L. (Liljeroos et al. 2011)) was diluted 
to Vero/SLAM media without antibiotics or foetal calf serum but additionally 0.2% 
(v/v) BSA and used to infect Vero/SLAM cells at 60% confluency at passage number 
52 with multiplicity of infection (m.o.i.) 0.1 in 175 cm2 culture flasks. Only infection 
media without the virus was added to mock infected cells. Infection was allowed to start 
for 2 h at 37°C 5% CO2 before replacing the infection media with Vero/SLAM media 
without geneticin. Infection was then allowed to continue 48 h at 37°C 5% CO2.  
Culture media was collected from infected cells and the cells washed two times 
with ice cold PBS and lysed with lysis buffer (3 ml per flask) containing: 0.5% (v/v) 
Triton-X, 20 mM imidazole, 2 mM EDTA, protease inhibitors (1 tablet/ 10 ml solution, 
Roche) and phosphatase inhibitors (phosSTOP 1 tablet/ 10 ml solution, Roche) in PBS, 
pH 8.3 (0.2 µm filtered). Lysis was allowed to continue 2.5 h on ice and the cell debris 
was collected by centrifuging 4000 rpm 5 min at + 4°C on a tabletop centrifuge. Nuclei 
were lysed from the debris by modified RIPA buffer (see p. 28, the protease inhibitors 
and phosphatase inhibitors added as before and in addition 2 mM EDTA), pH 7.7 
(0.2 µm filtered). Lysis was allowed to continue 1.5 h on ice and the cell debris was 
removed by centrifuging 4000 rpm 5 min + 4°C on a tabletop centrifuge. 
Virus from the infected media was concentrated and roughly purified by differential 
centrifugation: Cells were removed from the infected media by centrifuging 5000 rpm 
5 min at + 4°C in a SS34 rotor. Virus was pelleted by ultracentrifuging 28 000 rpm 2 h 
at + 4°C in a SW28 rotor through a 15% (v/v) OptiPrepTM cushion in a buffer 
containing 20 mM Tris-HCl, 180 mM NaCl, 2 mM MgCl2, pH 7.5 (0.2 µm filtered). 28 
ml of infected media were used per 10 ml of 15% (v/v) OptiPrepTM solution. Virus 
pellet were resuspended and collected. Samples were taken also from the media and 
OptiPrepTM layer. The samples were diluted to SDS-PAGE loading buffer, boiled 6 min 
at 97°C and stored at − 20°C. Vero/SLAM cells were also tested for mycoplasma 
contamination by using PromoKine’s PCR Mycoplasma test kit II. 
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3.5 Phosphate affinity electrophoresis 
 
The phosphate-binding tag tool developed by Kinoshita et al. (2006) was used to 
analyse phosphorylation modifications in purified protein and viral samples. Self-casted 
acrylamide gels were used with resolving gels without SDS, but with 50 or 100 µM 
Phos-tagTM (Wako Pure Chemical Industries, Ltd) and 100 or 200 µM MnCl2 instead. 
For N and P proteins 0.5% (w/v) low electroendosmosis agarose (Supplied by 
BioNordika, manufactured in EU) was used to strengthen the gels according to 
Kinoshita et al. (2009) protocol. The gel and running buffer compositions are presented 
in more detail in Appendix 5. Sample band shifts in Phos-tagTM gels were compared to 
shifts in normal SDS-PAGE gels. E. coli P in a HEK293EBNA1 cell lysate was used as 
a negative phosphorylation control. For matrix protein ovalbumin was used as a positive 
phosphorylation control and dephosphorylated ovalbumin as negative control. Naturally 
phosphorylated ovalbumin was dephosphorylated with 20 U/ml FastAPTM alkaline 
phosphatase enzyme (Thermo Scientific) according to Thermo Scientific’s protocol. 
 
3.6 Immunoblotting 
 
After gel electrophoresis, manganese ions were removed from the Phos-tagTM gels by 
incubating the gels 10 min in 1 mM EDTA in western blot transfer buffer (10 mM 
3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), 10% (v/v) methanol, pH 10.5). 
The samples were transferred to polyvinylidene fluoride (PVDF) membranes 
(Millipore) with 200 mA for 1 h in wet tank at room temperature with cooled + 4°C 
transfer buffer. Membranes were blocked for 1 h at room temperature or overnight at + 
4°C in cold room with 2% (w/v) non-fat milk powder in PBS-T buffer (0.05% (v/v) 
Tween 20 in PBS). After blocking, membranes were incubated with primary antibodies 
for 1 h at room temperature in an agitator. Primary antibodies used were: anti-P (9H4) 
mouse monoclonal ascites (Santa Cruz Biotechnology, Inc.), anti-N (2F3) mouse 
monoclonal ascites (Santa Cruz Biotechnology, Inc.) or anti-M (ab101015) rabbit 
polyclonal serum (Abcam, Plc) diluted in PBS-T buffer. The proteins were visualized 
with ECLTM anti-mouse or anti-rabbit sheep IgG horseradish peroxidase(HRP)-
conjugated whole antibody (GE Healthcare) for 1 h at room temperature in an agitator. 
LuminataTM Classico Western HRP substrate (Millipore) was used as substrate for the 
HRP enzyme. 
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4 RESULTS 
 
4.1 Cloning 
 
The aim was to clone a truncated P1-48 gene and a whole P gene into a pTT5SH8Q2-
vector so that the proteins they express have His-tags at the N-terminus. The truncated 
version was cloned for studying the P-N interaction – the N-terminus of the P protein is 
responsible for binding to N0 (Liljeroos, L. & Butcher, S.J., personal communication, 
Harty et al. 1995). 
In ligation reaction the undigested vector control gave three bands as expected: 
nicked, linear and supercoiled forms of the plasmid – of which the supercoiled form was 
the most abundant (Figure 8, lane 3). The linearized vector and the inserts all had the 
expected sizes: The linearized vector (lane 4) was 4.5 kb (Appendix 3: pTT5SHQ2-
plasmid), P1-48 was 200 bp (lanes 5 and 6) and P was 1.5 kb (lanes 8 and 9). 
Purifications of the inserts and vector succeeded because only one band was seen. In 
ligation reactions (lanes 7 and 10) many bands were seen, as expected, since there 
should be many different ligation products in the mix. 
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Figure 8. DNA constructs used in ligation reaction. Run with 0.8% (w/v) low 
electroendosmosis agarose (BioNordika) with 120 V for 20 min in 1 × TAE buffer. 
Lane and sample: 
1 GeneRulerTM 1 kb DNA standard, Thermo Scientific 
2 GeneRulerTM 100 bp DNA standard, Thermo Scientific 
3 Undigested vector pTT5SH8Q2 
4 NotI and EcoRI digested and purified vector pTT5SH8Q2, 4413 bp 
5 Purified insert P1-48, 192 bp 
6 NotI and EcoRI digested and purified insert P1-48, 182 bp 
7 Ligation reaction of insert P1-48 and vector pTT5SH8Q2 
8 Purified insert P, 1559 bp 
9 NotI and EcoRI digested and purified insert P, 1572 bp 
10 Ligation reaction of insert P and vector pTT5SH8Q2 
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Transformation efficiencies for the P1-48/pTT5SH8Q2 and P/pTT5SH8Q2 constructs 
were 3.8  102 and 4.4  102 per µg of DNA transformed (Table 4). Transformation 
frequency was calculated by dividing the number of colonies with the number of cells 
used in transformation. Transformation efficiencies were calculated by dividing number 
of colonies with the amount of DNA used for transformation. The number of unspecific 
ligation reactions were subtracted. In unspecific ligation reactions vectors had ligated to 
themselves and were able to produce colonies, because ampicillin resistance gene was 
read from circular DNA (“Digested & ligated vector” -row in the table). The 
transformation efficiencies of the P1-48/pTT5SH8Q2 and P/pTT5SH8Q2 constructs are, 
however, estimations since it is impossible to know the exact ligated DNA amount. 
 
 
Table 4. Transformation efficiencies after 15 h of transformation. 
 
 number 
of 
colonies 
Media 
used 
Transformation 
frequency 
Transformation 
efficiency / µg of 
DNA 
DH5 10-5 plate dilution 65 L   
Undigested vector 405 L + Amp* 6.2  10-4 4.1  105 
Digested & ligated vector 15 L + Amp* 2.3  10-5 6.0  102 
P1-48/pTT5SH8Q2 32 L + Amp* 2.6  10-5 3.8  102 
P/pTT5SH8Q2 31 L + Amp* 2.5  10-5 4.4  102 
*Amp = 100 µg/µl ampicillin  
 
 
The colony-PCR gave 7 and 3 positive subclones out of the ten tested per P1-48 or P 
gene construct (Figure 9 and 10). With P1-48/pTT5SH8Q2 there were two bands in most 
of the PCR results. The 200 bp band was the expected product and the other was 
unspecific product where primers had bound to somewhere else in the genome. 
Subclones number 7, 8 and 10 were chosen for digestion analysis (Figure 9, lanes 9, 10 
and 12). P/pTT5SH8Q2 gave three positive subclones numbered 8, 9 and 10 that were 
all taken for digestion analysis (Figure 10, lanes 9–11). 
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Figure 9. Colony-PCR of P1-48/pTT5SH8Q2. Run with 0.8% (w/v) low 
electroendosmosis agarose (BioNordika) with 120 V for 20 min in 1 × TAE buffer. 
GeneRulerTM 1 kb (Thermo Scientific) in the first lane and GeneRulerTM 100 bp 
(Thermo Scientific) in the second. Subclones 1–10 in lanes 3–12. The P1-48 insert is 192 
bp in size. The expected band is the top most of the two bands in the lanes 3–12, sized 
approximately 200 bp.  
 
 
 
Figure 10. Colony-PCR of P/pTT5SH8Q2. Run with 0.8% (w/v) low electroendosmosis 
agarose (BioNordika) with 120 V for 20 min in 1 × TAE buffer. GeneRulerTM 1 kb 
(Thermo Scientific) in the first lane. Subclones 1–10 in lanes 2–11. The P insert is 
1572 bp in size.  
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All the six selected subclones that were positive according to colony-PCR, were also 
positive according to the restriction enzyme digestion analysis (Figure 11). Digested 
vector was 4.5 kb (lanes 1–3 and 6–8), digested P1-48 insert was 200 bp (lanes 1–3) and 
P insert was 1.6 kb (lanes 6–8). Two subclones of both P1-48/pTT5SH8Q2 and 
P/pTT5SH8Q2 were sent to sequencing.  
 
 
 
Figure 11. Digestion analysis of six positive subclones from colony-PCR. Run with 
0.8% (w/v) low electroendosmosis agarose (BioNordika) with 120 V for 20 min in 1 × 
TAE buffer. Digested vector is 4413 bp, digested P1-48 insert is 182 bp and digested P 
insert is 1559 bp. Lane and sample: 
1 P1-48/pTT5SH8Q2, subclone number 7  
2       subclone number 8 
3               subclone number 10 
4 GeneRulerTM 100 bp (Thermo Scientific) 
5 GeneRulerTM 1 kb (Thermo Scientific) 
6 P/pTT5SH8Q2, subclone number 8  
7             subclone number 9 
8             subclone number 10 
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The sequencing covered the whole genes P1-48 and P. In case of the P gene, forward and 
reverse primer produced sequences overlapped by 47 bp. The results of sequencing 
confirmed the success of cloning (Appendix 6: Sequencing results). Subclones 8 from 
both of the cloned DNA constructs were chosen for use because they had produced 
more sequencing data and contained no mutations (like the one in the P subclone 9 that 
was missing C849 from the sequence).  
The sequences of the both clones used later in the work matched with the Helsinki 
strain. Comparing to Edmonston strain there was one point mutation from A to G in 
residues 1474. It changed 492nd amino acid from asparagine to aspartic acid. The 
protein was still functional because although the mutation was rare there was at least 
one documented strain that had the same mutation in the GenBank® of National 
Institutes of Health (NIH) genetic sequence database: Measles strain NC1/95 (GenBank 
ID: FN668724.1). According to the protein data bank the mutation was in the beginning 
of the third and last -helixes at the end of the P protein (Protein data bank ID: 1T6O). 
 
4.2 Tissue culture 
 
4.2.1 Transfection optimization with PEI 
 
The best DNA to PEI ratio for transfecting HEK293EBNA1 cells was 1:5 (Figure 12). 
There was no transfection without PEI and DNA to PEI ratio 1:1 worked really poorly; 
only a few cells in the plate got transfected. Transfection efficiency was 50% at its best 
(Table 5). PEI, though being toxic to cells, did not affect cell growth significantly, 
because there were about the same amount of cells growing in all of the cluster plates 
regardless of the amount of PEI used.  
The transfected cells had different fluorescence levels in a culture. If the 
fluorescence was low the cell was able to survive but protein production was also low. 
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Figure 12. Transfection optimization test of HEK293EBNA1 cells with 
YFP/pTT5SH8Q2 control plasmid. The pictures show the amount of fluorescent cells in 
the transfected cultures that differ by PEI amounts. DNA to PEI ratios are shown in the 
upper left corners. Pictures are taken by UV- and visible light at the same time. No 
picture of 1:1 ratio or PEI control are presented. Cells were 80% confluent when 
transfected and the passage number was 20. 
 
 
Table 5. Transfection efficiencies of the optimization test. 
DNA : PEI ratio Transfection efficiency - Amount of 
fluorescent cells per all the cells 
1 : 1 0.01% 
1 : 2.5 20% 
1 : 3 30% 
1 : 4 40% 
1 : 5 50% 
PEI control 0  
 
 
  
1:4 1:5 
1:2.5 1:3 
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4.2.2 Transfection with measles gene constructs to create heterologous 
overexpression 
 
The HEK293EBNA1 cells were transfected, in two sets for comparison, with 
P1-48/pTT5SH8Q2, P/pTT5SH8Q2, N/pTT5SH8Q2, P1-48/pTT5SH8Q2 + 
N/pTT5SH8Q2 and P/pTT5SH8Q2 + N/pTT5SH8Q2, M/pTT5SH8Q2 and also 
YFP/pTT5SH8Q2 separately. The cells were 70% and 100% confluent when harvested. 
Transfection efficiencies were 60% and 70% (Figure 13). Transfection efficiencies were 
higher in measles gene construct transfections than in the PEI optimization. Also, it was 
10% better when the cells were more confluent during the second transfection.  
 
 
   
Figure 13. Transfection efficiencies with YFP/pTT5SH8Q2 control plasmid. 
Transfection efficiencies are 60% in the left panel and 70% in the right panel. In the 
first transfections cells were 70% confluent and in the second transfection they were 
100% confluent after two days of transfection. The passage numbers were 22 and 28. 
 
 
4.3 Protein purification from mammalian cells with Ni-NTA beads 
 
The results were similar for the two sets of purifications and are only shown for the 
second one. Protein production for the other proteins except for P was very low with 
HEK293EBNA1 cells (Figures 14 and 15). The 75 kDa P was clearly seen in SDS-
PAGE electrophoresis (Figure 14, lanes 5–7 and Figure 15, lanes 2–5). Also the 30 kDa 
YFP protein purified well with the beads and clearly had a His-tag (Figure 15, lanes 10–
12). There were also a lot of unspecific protein binding so the E. coli produced P was 
not clearly seen in gel and western blotting had to be used. Also N and M were only 
1. Transfection 2. Transfection 
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seen sufficiently enough with western blotting. P1-48 was not seen even with blotting 
(data not presented). Perhaps it did not bind the P antibody as the protein was so 
truncated, containing only the first 48 amino acids of the full-length protein. However, it 
was not seen either with antibodies for His-tag. RIPA buffer used for purifying proteins 
from nuclei did not work with the beads (Figures 14 and 15, all nuclear fractions). 
 
 
 
Figure 14. Protein purification for HEK293EBNA1 produced proteins: cell lysate, 
cytosolic and nuclear fractions are shown separately. Run with Mini-Protean® TGXTM 
4–20% gradient gel (Bio-Rad) with 20 mA for 1h in 1 × Laemmli buffer. Lane and 
sample: 
1 Protein marker, broad range 2-212 kDa (NEB) 
2 lysate  P1-48 
3 cytosolic P1-48 
4 nuclear P1-48 
5 lysate  P
 
6 cytosolic P 
7 nuclear P 
8 lysate  N
 
9 cytosolic N 
10 nuclear N 
11 lysate  P1-48+N 
12 cytosolic P1-48+N 
13 nuclear P1-48+N 
14 – 
15 – 
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Figure 15. Protein purification for HEK293EBNA1 produced proteins: cell lysate, 
cytosolic and nuclear fractions are shown separately. Run with Mini-Protean® TGXTM 
4–20% gradient gel (Bio-Rad) with 20 mA for 1h in 1 × Laemmli buffer. Lane and 
sample: 
1 Protein marker, broad range 2-212 kDa (NEB) 
2 lysate  P+N
 
3 cytosolic P+N 
4 nuclear P+N  
5 lysate  P
 
6 lysate  N 
7 lysate  M
 
8 cytosolic M 
9 nuclear M 
10 lysate  YFP control + E. coli produced P phosphorylation control
 
11 cytosolic YFP control + E. coli produced P phosphorylation control 
12 nuclear YFP control + E. coli produced P phosphorylation control 
13 – 
14 Protein marker, broad range 2-212 kDa (NEB) 
15 – 
 
 
4.4 Virus production 
 
After two days of infection, Vero/SLAM cells formed large syncytia (Figure 16 and 17). 
Virus was recovered from cytosol, nuclei and culture media separately and P, N and M 
proteins were detected from them with western blotting (Figure 18). Mock infected cells 
gave no signal. 
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Figure 16. Cells in a less confluent cell layer after two days of infection. Still normal 
looking cells in the bottom half of the picture and a large syncytium in the middle of the 
picture (shown with arrows). 
 
 
 
Figure 17. Syncytia in a more confluent cell layer after two days of infection. The 
outlines of individual cells are hard to see. The cells are gradually forming a one giant 
multinucleated cell. 
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Figure 18. Western blot from virus purification with anti-P, anti-N and anti-M 
antibodies. Samples are blotted from 4–20% Mini-Protean®TGXTM precasted gel 
(Bio-Rad). Gels were run with 30 mA in 1 × Laemmli buffer for 1 h 20 min (P and N 
samples) and 45 min (M samples). Primary antibody dilutions used were 1:4,000 for 
anti-P and anti-N and 1:2,000 for anti-M. Secondary antibody dilution used was 
1:2,000. Lane and sample: 
1 E. coli produced P, N or M (kindly provided by Liljeroos, L.) 
2 Virus from cytosolic fraction 
3 Mock infected cytosolic fraction 
4 Virus from nuclear fraction 
5 Mock infected nuclear fraction 
6 Culture media from OptiPrepTM purification with virus supernatant 
7 Culture media from OptiPrepTM purification with mock infected cell supernatant 
8 OptiPrepTM layer sample from OptiPrepTM purification with virus supernatant 
9 OptiPrepTM layer sample from OptiPrepTM purification from mock infected cell  
   supernatant 
10 Released virus from OptiPrepTM purification 
11 Sample from bottom of the tube from OptiPrepTM purification with mock infected  
     cell supernatant 
 
 
  
1  2  3  4  5  6  7  8  9 10 11 1  2  3  4  5  6  7  8  9 10 11 1  2  3  4  5  6  7  8  9   10  11 
P N M 
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4.5 Mycoplasma test 
 
There was no mycoplasma contamination in the mammalian cell cultures according to 
PromoKine’s PCR Mycoplasma test kit II as shown in Figure 19. 
 
 
 
Figure 19. Mycoplasma test. Positive result would give 270 bp band. Run with 2% 
(w/v) low electroendosmosis agarose (BioNordika) with 120 V for 30 min in 1 × TAE 
buffer. Lane and sample: 
1 GeneRulerTM 100 bp (Thermo Scientific) 
2 Positive control provided by the test kit 
3 Negative control without template 
4 Sample from HEK293EBNA1 culture media 
5 Sample from Vero/SLAM culture media 
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4.6 Phosphorylation analysis 
 
4.6.1 Phosphoprotein has three predominant phosphate isoforms 
 
E. coli produced P added to the HEK293EBNA1 cell lysate was not phosphorylated 
even though no kinase inhibitor was used in protein purification (Figure 20). Therefore 
recombinant proteins in the samples were still in their natural phosphorylation state as 
they had been when produced from the cells. Protein standards were poorly seen in the 
developed films, but some main standard bands were seen and the sizes of the proteins 
were also checked by comparing immediately to the blotted membranes. 
 
 
 
 
Figure 20. E. coli P added to the HEK293EBNA1 cell lysate is not phosphorylated. On 
the left is blotted Phos-tagTM gel (5% (w/v) acrylamide, 0.5% (w/v) agarose, 50 µM 
Phos-tagTM) and on the right is blotted normal SDS-PAGE gel (7.5% (w/v) acrylamide). 
Both were run with 30 mA in 1 × Laemmli buffer for 1 h 25 min. Antibody dilutions 
used were 1:6,000 for primary antibody and 1:3,000 for secondary antibody. Lane and 
sample: 
1 E. coli P added to the HEK293EBNA1 cell lysate 
2 E. coli P 
 
 
P was phosphorylated when produced in mammalian cells as a recombinant protein and 
also in virus as expected (Figures 21 and 22). P shifted only lightly when compared to 
E. coli produced unphosphorylated protein. There was one unphosphorylated and two 
predominant phosphorylated isoforms. They were seen in all samples except the viral 
nuclear fraction that produced too distorted sample bands (Figures 21 and 22, lanes 2–6 
and 8). Also there seemed to be at least one additional phosphorylated isoform in 
recombinant P produced with N (Figure 21, lane 4). With high exposure time of the film 
at least three faint additional sample bands were also seen (Figure 22). No difference 
was detected between cytosolic or nuclear fractions in mammalian recombinant 
proteins. Phosphorylated isoform ratios were different in the samples: In recombinant P 
the least phosphorylated isoform was predominant in all samples (the middle sample 
band in Figures 21 and 22, lanes 2–5). However, in a complex with N, P had more of 
 1        2          1              2 
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the second phosphorylated isoform (the upper most predominant sample band in Figure 
21 and 22, lanes 4 and 5). In virus, then however, the unphosphorylated form was 
predominant and released virus had very little of the most phosphorylated isoform. 
Mock transfected or infected cells gave no signal in normal or Phos-tagTM gels. 
 
 
 
 
 
Figure 21. Bacterial and mammalian produced P compared to viral P. Upper Figure is 
blotted from Phos-tagTM gel (5% (w/v) acrylamide, 0.5% (w/v) agarose, 50 µM Phos-
tagTM) and bottom from normal SDS-PAGE gel (7.5% (w/v) acrylamide). Both were run 
with 30 mA in 1 × Laemmli buffer for 1 h 25 min. Antibody dilutions used were 
1:6,000 for primary antibody and 1:3,000 for secondary antibody. In lane one the upper 
band is polymerized P protein and the bottom one is a breakdown product also seen in 
other sources for example in Huber et al. 1991. Lane and sample: 
1 E. coli P 
2 HEK P cytosolic 
3 HEK P nuclear 
4 HEK P+N cytosolic 
5 HEK P+N nuclear 
6 Viral P cytosolic 
7 Viral P nuclear 
8 Viral P released 
 
  
     1    2       3  4      5   6   7      8 
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Figure 22. Bacterial and mammalian produced P compared to viral P. The upper two 
panels are blotted from Phos-tagTM gel (5% (w/v) acrylamide, 0.5% (w/v) agarose, 50 
µM Phos-tagTM) and the bottom panel from normal SDS-PAGE gel (7.5% (w/v) 
acrylamide). Both were run with 30 mA in 1 × Laemmli buffer for 1 h 25 min. Antibody 
dilutions used were 1:4,000 for primary antibody and 1:2,000 for secondary antibody. 
Two different exposure times are shown for the Phos-tagTM samples. Lane and sample: 
1 E. coli P 
2 HEK P cytosolic 
3 HEK P nuclear 
4 HEK P+N cytosolic 
5 HEK P+N nuclear 
6 Viral P cytosolic 
7 Viral P nuclear 
8 Viral P released 
     1  2      3   4     5   6   7      8 
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4.6.2 Nucleoprotein is the most phosphorylated as a recombinant protein 
when expressed alone and otherwise very scarcely 
 
The shift between phosphorylated isoform of N and unphosphorylated E. coli produced 
N was again narrow. N was phosphorylated with three predominant isoforms and 
possibly three other scarce isoforms (light bands) when produced alone in mammalian 
cells (Figure 23 and 24, lanes 2 and 3). Other samples were predominantly 
unphosphorylated, but had one scarce phosphorylated isoform. In addition, there might 
had been an additional band right above the predominant sample band in the viral 
cytosolic sample (Figure 23 and 24, lane 6). An oligomerized protein band in the E. coli 
control was unfortunate (Figures 23 and 24, lane 1). There seemed to be two 
phosphorylated bands in the viral samples, but the other one was a polymerized protein, 
since it was seen also in the standard SDS-PAGE gel (Figure 23 and 24, lanes 6–8, the 
bottom most gel picture). No difference was detected between cytosolic or nuclear 
fractions in mammalian recombinant proteins. Mock transfected or infected cells gave 
no signal in normal or Phos-tagTM gels (data not shown). 
 Sample bands were smeared so second blot was done with a lot smaller sample 
amounts and long exposure time for the film had to be used to see them. Because of the 
conditions some sample bands got distorted and the nuclear sample of N in complex 
with P run differently than the cytosolic one (Figure 24, lane 5), when earlier they had 
run similarly (Figure 23, lanes 4 and 5). Also the recombinant N in complex with P 
seemed to be predominantly phosphorylated (Figure 24, lane 5) and also the E. coli 
produced N sample band was distorted. However, the phosphorylated isoforms of the 
recombinant N produced alone were now nicely visible (Figure 24, lane 2). 
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Figure 23. Bacterial and mammalian produced N compared to viral N. The upper two 
panels are blotted from Phos-tagTM gel (5% (w/v) acrylamide, 0.5% (w/v) agarose, 100 
µM Phos-tagTM) and the bottom panel from normal SDS-PAGE gel (10% (w/v) 
acrylamide). Both were run with 30 mA in 1 × Laemmli buffer for 1 h 20 min and 1 h 
30 min respectively. Antibody dilutions used were 1:4,000 for primary antibody and 
1:2,000 for secondary antibody. Two different exposure times are shown for the Phos-
tagTM samples. In lane one the upper band is polymerized N and the bottom one is a 
breakdown product also seen in other sources for example in Huber et al. 1991. Lane 
and sample: 
1 E. coli N 
2 HEK N cytosolic 
3 HEK N nuclear 
4 HEK P+N cytosolic 
5 HEK P+N nuclear 
6 Viral N cytosolic 
7 Viral N nuclear 
8 Viral N released 
 
  
     1      2         3     4       5     6    7         8 
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Figure 24. Bacterial and mammalian produced N compared to viral N: Smaller sample 
amounts with long exposure time. Upper Figure is blotted from Phos-tagTM gel (5% 
(w/v) acrylamide, 0.5% (w/v) agarose, 100 µM Phos-tagTM) and bottom from normal 
SDS-PAGE gel (10% (w/v) acrylamide). Both were run with 30 mA in 1 × Laemmli 
buffer for 1 h 11 min. Antibody dilutions used were 1:6,000 for primary antibody and 
1:3,000 for secondary antibody. Lane and sample: 
1 E. coli N 
2 HEK N cytosolic 
3 HEK N nuclear 
4 HEK P+N cytosolic 
5 HEK P+N nuclear 
6 Viral N cytosolic 
7 Viral N nuclear 
8 Viral N released 
 
 
4.6.3 Matrix protein is unphosphorylated 
 
No phosphorylation was detected in M protein (Figure 25). M 37 kDa was even smaller 
than 45 kDa ovalbumin which shifted always well (Figure 26) so if M was 
phosphorylated the shift should had been well seen in Mn2+–Phos-tagTM gels. M 
proteins were prone to self-aggregation and aggregates were seen as bands on the top of 
the gel with mammalian produced protein and also as two bands in E. coli produced 
protein (not shown). Mock transfected or infected cells gave no signal in normal or 
Phos-tagTM gels. 
 
  1         2         3         4        5      6        7              8 
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Figure 25. Bacterial and mammalian produced M compared to viral M. Upper Figure is 
blotted from Phos-tagTM gel (7.5% (w/v) acrylamide, 100 µM Phos-tagTM) and bottom 
from normal SDS-PAGE gel (10% (w/v) acrylamide). Both were run with 30 mA in 1 × 
Laemmli buffer for 1 h. Antibody dilutions used were 1:2,000 for both primary and 
secondary antibodies. Lane and sample: 
1 E. coli M 
2 HEK M cytosolic 
3 HEK M nuclear 
4 Viral M cytosolic 
5 Viral M nuclear 
6 Viral M released 
 
 
          
Figure 26. Ovalbumin controls for M phosphorylation analysis cut from the same gel as 
M samples in Figure 25. On the left is normal SDS-PAGE gel and on the right Phos-
tagTM gel. Both were run with 30 mA in 1 × Laemmli buffer for 1 h. The 
phosphorylated ovalbumin is shifted compared to unphosphorylated ovalbumin. The 
sizes of the sample bands were determined from another gel with broad range protein 
markers 2–212 kDa (NEB): ovalbumin are 39 and 45 kDa in the normal SDS-PAGE gel 
and 55 and 65 kDa in the 100 µM Phos-tagTM gel (smaller one being a breakdown 
product of the protein). The dephosphorylated ovalbumin is 39 kDa in both gels. The 
alkaline phosphatase is 67 kDa. Lane and sample: 
1 Ovalbumin 
2 Alkaline phosphatase treated unphosphorylated ovalbumin 
  1         2        3      4         5       6 
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5 DISCUSSION 
 
5.1 Cloning 
 
The pTT5SH8Q2-plasmid was used because it is replicated in high copy numbers in 
E. coli and enables constitutive expression of viral genes in mammalian cells. BSA was 
used in the digestions because it stabilises the enzymes. The cloning succeeded because 
right constructs were obtained according to sequencing data (Appendix 6). A large 
amount of the truncated P1-48 insert were used in the ligation (with 1:7.6 vector to insert 
ratio), which resulted in 7 positive subclones out of ten (Figure 9). Luckily there were 
no multiple inserts ligated next to each other in the sequenced subclones. Also the insert 
bands had the same intensity (Figure 11, bottom most sample bands in lanes 1–3 and 6–
8) and that already indicated that there is the same amount of insert in the different 
subclones. Smaller amount of the P insert was used for ligation (with 1:0.5 vector to 
insert ratio), which resulted only three positive subclones out of ten (Figure 10). That 
seems expected compared to the other subclone. 
Expected transformation efficiency of E. coli CaCl2 competent cells are 103–105 per 
µg of DNA transformed (American Society for Microbiology 2013). Results in this 
thesis were in the range of 102 which is expected due to speeded up protocol. The 
transformation efficiencies could have been improved by cultivating the cells after 
transformation in L media without antibiotics. The cells would have had time to recover 
from transformation procedure and express antibiotic resistance proteins from the 
plasmids transformed. The transformation efficiency could have also been improved by 
optimizing the transformation protocol by using different transformation method such as 
electroporation for electrocompetent cells, adding different aiding reagents to the 
transformation mixes or possibly using an optimized strain, but in this case it was not 
necessary since the clones with the DNA constructs wanted were found. 
In addition, the size of the transformed DNA matters so that the number of 
transformants should decrease as DNA size increases. Transformants P1-48/pTT5SH8Q2 
and P/pTT5SH8Q2 (459 bp bigger than the other) were transformed in similar levels 
with the difference of just one colony forming unit. The transformation efficiency is 
also dependent on the success of ligation and the form of plasmid. Smaller insert should 
ligate better. I had different insert to vector ratios between the different ligation 
reactions so their comparison is difficult.  
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5.2 Tissue culture 
 
The HEK293EBNA1 strain was used because the HEK293 as a working horse for 
biotechnology are easy to work with and can express recombinant proteins well. The 
EBNA1 enables viral DNA replication by binding to OriP origin of replication in 
pTT5SH8Q2 expression vector (see Appendix 3). The best DNA to PEI ratio in 
transfection was 1:5, out of the tested ratios, which was the highest DNA to PEI ratio 
tested. It seems high since other transfection protocols of HEK293EBNA1 cells use for 
example 1:2 ratio (Tom et al. 2008). The 1:5 ratio was used since it had also been the 
best ratio before in this lab for these cells. PEI is toxic to the cells, but the concentration 
used did not luckily disturb the cells. About 50% of the cells were transfected in the 
transfection optimization test. The efficiency should have preferably been higher. It 
could have been improved by working more quickly but more gently with the cells. 
Cells are easily disturbed if they are too long at room temperature or start to dry out 
between adding different solutions. Also some cells get easily dispatched from the 
bottom of the culture dish if the solutions are pipetted too quickly. Room temperature 
PBS solution was used but it could have been prewarmed to 25–37°C (Tom et al. 2008). 
Also, the DNA solutions were not vortexed after adding the PEI. The tubes were just 
shook immediately after addition of PEI. It might not have been enough and some of the 
PEI might have not made a complex with DNA. Cell viability could have also been 
assessed, for example, with Trypan Blue Stain (Life TechnologiesTM, Transfection tips 
and tricks 2014). Luckily, after optimization, the transfection efficiencies were higher: 
60% and 70% (Figure 13). 
In addition, the cells used might have not been in optimum condition because there 
were no clear data of how old the cell line was. The passage numbers of the previous 
user were continued. Passage number was 20 during transfection optimization and 22 
and 28 when transfected with measles gene constructs. The real passage number might 
have been even higher and the cells might have been old and changed their properties. 
However, any weird changes were not seen in their appearance through the microscope 
and at least good protein production of P protein was produced so the cells should have 
been in good enough condition.  
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5.3 Protein purification 
 
Kinase inhibitors were not used during the protein purification process. EDTA could 
possibly be used as a kinase inhibitor to keep the proteins in their natural 
phosphorylation state when purified from the cells. However, EDTA chelates metal ions 
and cannot be used in metal affinity chromatography, because it would therefore 
remove the metal ions from the affinity column. It might be possible to use EDTA with 
low concentration of 0.1 mM (Qiagen 2011), but instead I added E. coli produced 
unphosphorylated P to the YFP cell lysate as a control. P from E. coli was not 
phosphorylated in the cell lysate (Figure 20) so the phosphorylation status should have 
stayed the same also for all the other proteins. Phosphatase inhibitors were used. 
Some of the nickel beads – and proteins as well with them – were lost during the 
washes but most of the protein was in the final fraction (data not shown). Lysis buffers 
could have been optimized to pH 8.0 which is the optimum for Ni-NTA sepharose for 
possibly a bit better protein binding to beads. Now the pH was 7.7–8.3.  
RIPA buffer did not work well with the beads because nuclear proteins purified 
poorly (Figure 14 and 15, nuclear fractions). Otherwise the proteins were expected to be 
in the cytosolic fractions, but the N expressed alone should have localized to nucleus 
(Huber et al. 1991). The N protein that was used had the nuclear localization signal 
intact (Sato et al. 2006) and herein should have localised to nucleus (Figure 14, lane 
10). There were however far less N in the cytosolic fraction of N alone (Figure 14, lane 
9) compared to the cell lysate (Figure 14, lane 8) when N in the complex with P 
enriched in cytosolic fraction (Figure 15, lane 2 and 3). There also are more protein in 
the nuclear fraction of N than in the other nuclear fractions (Figure 23, lane 3). So it can 
be that the N is localized mostly in the nucleus, but the RIPA buffer system just did not 
work as hoped. Gradient ultracentrifugation could have been used instead to collect the 
nuclear fractions. However, some protein was produced from the nuclear fractions. 
There were also P protein in the nuclear fraction (Figure 21 and 22, lane 3), which 
seems odd, since it should locate into cytosol (Huber et al. 1991). The amount was 
though very small so it is not clear, if it is just impurities left from the cytosolic fraction. 
The RIPA buffer is commonly used buffer for cell lysis and it should be especially good 
for breaking the nuclear membrane and compatible with phosphorylation analysis. 
However, P protein pulled almost none N protein with it in the purification (Figure 23 
and 24, lane 5), so it seems that the RIPA buffer denatured and dissociated them not 
letting the protein complex to form. The buffer contains SDS and sodium deoxycholate 
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which are ionic detergents. It seems that the concentrations used were high enough also 
to disrupt the binding of His-tag to the nickel beads. 
The recombinant truncated P1-48 – which was produced to study P-N interaction – 
was not produced with HEK293EBNA1 cells. Antibodies for His-tag produced 13 kDa 
protein band (data not presented), when the P1-48 should have produced 8 kDa protein 
(Liljeroos, L. & Butcher, S.J., personal communication). The used western blot transfer 
buffer should work for all of the proteins because its pH 10.5 was well above the 
proteins isoelectric points which were 4.72–9.24 according to Compute pI/Mw tool 
(ExPASy, SIB). Perhaps, for P1-48 a better suited membrane could have been used with 
smaller pore size. It is also possible that such a small protein had diffused out of the gel 
during staining. 
 
5.4 Virus production 
 
Vero/SLAM cells were used because they contain SLAM receptor for the attachment of 
the wild type virus. Vero cells are also incapable of producing IFN so virus infection 
does not cause the cells to go to apoptosis (Emeny & Morgan 1979a). Geneticin allows 
the receptor for virus entry to be expressed and was not used after infection, because it 
could possibly disturb the cells and is not needed after the entry of viruses. The use of 
Edmonston (vaccine) strain could have increased virus production, because its P64S and 
E89K substitutions in the M protein improves titers by enhancing the interaction of M 
and H cytoplasmic tail, which inhibits cell-to-cell fusion and improves assembly and 
release of virus particles (Tahara et al. 2007). In addition, cultivation at 35°C instead of 
37°C would have improved titers (Liljeroos, L., personal communication). Also, all of 
the cells had not yet formed syncytia, so possibly more virus particles and more 
confluent tissue cultures (only 60% when infected) could have been used. In addition, 
the passage number was already 52 and also with these cells there were no clear data of 
how old the cell line really was. However, enough virus was produced, but maybe 
bigger production would have improved the sample bands’ appearance in phosphate 
affinity electrophoresis. 
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5.5 Phosphate affinity gel electrophoresis 
 
EDTA was used in cell lysis buffers as a kinase inhibitor when virus was produced and 
probably interfered with the samples in Phos-tagTM gel causing a curvature of the 
sample bands (Figure 21–24, lanes 6 and 7). EDTA is a chelating agent so it can remove 
manganese ions from the Phos-tagTM gel and interfere with the running of the samples. 
Also DTT in SDS-PAGE loading buffer may have interfered with the running. The 
biggest of the problems, however, were caused by salt in RIPA buffer (Figure 21–24, 
lane 7 and Figure 25, lane 5). Phos-tagTM gel electrophoresis seems to be extremely 
sensitive with sample amounts and salt or chelating agents in the samples. In addition, 
the velocities of all the proteins – whether they are phosphorylated or not – are 
decreased possibly due to the positive charge of the Mn2+–Phos-tagTM. The retardation 
was not just because of the Mn2+-ion, because if MnCl2 was added to a standard SDS-
PAGE gel the proteins still run better than in Phos-tagTM gel (data not shown). Herein, 
Phos-tagTM gel electrophoresis is simpler to execute with smaller proteins – it seemed 
that smaller than 60 kDa works well. They run better in Phos-tagTM gels and so are less 
sensitive for sample composition. P was already expected to run slowly relatively to its 
size on gel electrophoresis because of its high content of acidic protein residues in PNT 
(Karlin et al. 2002b). Phosphorylation in P and N, that are larger than 60 kDa, were 
harder to detect because the shift compared to the unphosphorylated control was small 
and they required longer running times, which increased the risk of curvature of the 
sample bands. The N phosphorylation was especially difficult to see (Figures 23 and 
24). N should be less phosphorylated than P, so the shift in Phos-tagTM gel compared to 
the unphosphorylated N was even more difficult to detect. Staining the phosphorylated 
proteins with phosphostain would have confirmed the results for N protein. The best 
result for P and N was obtained with 5% (w/v) acrylamide, 50 or 100 µM Mn2+–Phos-
tagTM gel strengthened with 0.5% (w/v) agarose. For P the 50 µM Mn2+–Phos-tagTM 
concentration was better, because it retarded the protein running less. The use of 
agarose was difficult and might have caused inconsistent gels due to uneven 
polymerization and so interfered with the sample running. Also, the stacking gel might 
have not stuck to the resolving gel evenly because a thin unpolymerised agarose layer 
had to be removed before casting the stacker and it proved to be difficult to do properly.  
It is possible that the Zn2+–Phos-tagTM could work better for P and N proteins 
(Kinoshita et al. 2012). They are sold as precasted gels, but the lowest acrylamide 
concentration available is 12.5% (w/v), when I now used 5% (w/v) gels. It might not 
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have separated the P and N well enough. They could have been casted in our lab, but the 
conditions would have had to been optimized again, because Zn2+–Phos-tagTM needs to 
be run in neutral buffer system. I regret not trying a Tris-buffer from the start because it 
is less sensitive to salts in the samples and could have produced better results. 
Since some of the sample bands were only seen very faintly overnight exposure of 
the films should have been tested for checking of all the faint bands. 
Phos-tagTM gel electrophoresis is simple, because the same equipment and a great 
deal of same reagents for standard SDS-PAGE gel electrophoresis can be used. 
However, it seems to need always a lot of optimization for gel and sample composition, 
which is not always straightforward since the conditions are not similar to normal SDS-
PAGE gel electrophoresis. The acrylamide concentration needs to be lower than usual, 
which caused inconvenience for me and I would not recommend this method for quick 
checking for phosphorylation status at least not for larger than 60 kDa proteins. The 
method is very useful, but it should be kept in mind that it can be a lot more sensitive 
for sample composition and research conditions and more time consuming than normal 
SDS-PAGE electrophoresis. 
 
5.6 Phosphorylation analysis and its effect on virus life cycle 
 
E. coli bacteria do not phosphorylate the proteins studied because they are 
phosphorylated only by the eukaryotic host cell kinases. Herein, bacterial produced 
proteins can be used as a negative controls for phosphorylation in viral and mammalian 
produced recombinant proteins. MV P and N are reported to be phosphorylated as 
recombinant proteins produced in mammalian cells (Hagiwara et al. 2008, Sugai et al. 
2012) and N also in insect cells and in virus particles (Prodhomme et al. 2010). Our 
results show P to be phosphorylated as a recombinant protein and in a virus particle. 
The N also seems to be phosphorylated, but predominantly just as a recombinant 
version produced alone.  
Many articles focus on recombinant proteins which do not correspond to the real 
situation of these proteins in virus infection. As our results show, the situation is not 
quite the same in MV infection as in heterologous overexpression of these proteins 
(Figures 21–25). However, Hagiwara et al. (2008) and Sugai et al. (2012) report that 
recombinant human cell produced N and viral N of HL strain have the same 
phosphorylation pattern. However, insect cell produced recombinant N produced by 
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Prodhomme et al. (2010) had different phosphorylation pattern. There were two sites 
less phosphorylated, probably because of different kinase pool in the cells. Naturally, 
recombinant proteins produced in cells that are not naturally infected by MV might be 
different. This situation could, however, give information through the differences about 
the function of individual phosphorylation sites. Recombinant systems are also 
convenient in producing sufficient amounts of protein and especially in the case of 
working with deadly viruses. It is always important though to compare recombinant 
proteins to the real-life situation. 
Prodhomme et al. (2010) got seven different phosphorylated isoforms for 
Edmonston strain viral N protein by using 2D western blotting, protein digestion, 
phosphopeptide enrichment and mass spectrometry (Prodhomme et al. 2010). The 
isoform ratios were: 20% unphosphorylated, 24.5% monophosphorylated, 17.3% di-, 
11.8% tri-, 11.3% tetra-, 9.7% penta-, and 5.3% hexaphosphorylated N protein. Perhaps, 
the different isoforms are important to different functions of N protein. Different viral 
strain was used in this thesis, but the Helsinki strain used and Edmonston strain N are 
similar by protein sequence. According to our results, there are only one very scarce 
phosphorylation isoform in all of the other samples except the recombinant N produced 
alone which had six phosphorylated isoforms (Figure 24, lane 2). Herein, only the 
recombinant N had similar phosphorylation pattern as Prodhomme et al. (2010) got for 
viral N except the recombinant N did not have the unphosphorylated isoform. There 
might be even more phosphorylated isoforms, but the bands might just be too light to be 
seen. It is possible that the method used is not high-resolution enough to see such faint 
sample bands.  
At the same time as this work was in progress, recombinant N produced in 
mammalian cells has been shown to have 11 putative phosphorylation sites (Sugai et al. 
2014). Sugai et al. (2014) states also that newly discovered phosphorylation at minor 
phosphorylation site T279, in the core region of N, is needed for it to form proper 
ribonucleocapsid and the stabilization of RNA happens when N is phosphorylated at 
this site. Prodhomme et al. (2010) did not find any phosphorylation modifications in the 
core region of N. 
According to our results, P and N are less phosphorylated in a virus compared to 
their recombinant versions (Figures 21–24). Also P is even less phosphorylated as a 
released virus than inside a cell. This implies that P needs higher level of 
phosphorylation to be active inside the host cells when performing its chaperone and 
cofactor duties. The results also show that recombinant P is more phosphorylated in a 
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complex with N than alone (Figures 21–22), when Sugai et al. (2012) reports it to be the 
other way around (Sugai et al. 2012). According to the results, the first phosphorylated 
isoform was most prominent in both cases, but in complex with N there were more of 
the most phosphorylated predominant isoform than in P alone. Sugai et al. (2012) used 
the same transfection time, but MV genes from different viral strain (HL), lipofectamine 
transfection method, cos-7 cells (monkey kidney cell line) for protein production and 
radioactive antibodies to detect phosphorylation. Because of differences in the methods 
and antibody incubation time, maybe we had different infection stages and our P is 
more phosphorylated earlier in the infection stage and still helping with transcribing 
more than replicating of the genome. In the case of N however, Sugai et al. (2013) have 
similar results; N alone is more phosphorylated than in the complex with P (Sugai et al. 
2013). Possibly alone it forms RNP and stabilizes RNA by phosphorylating. When 
together with P, P’s phosphorylation changes according to the infection state and if 
transcription or replication is needed predominantly. N was suspected to indirectly 
regulate viral transcription by changing the phosphorylation state of P. 
The results show the M to be unphosphorylated. Phosphorylation of M protein has 
been reported (Fujinami & Oldstone 1979), but before the identification of V protein 
(Cattaneo et al. 1989) and it seems that it was confused with the yet not identified V 
protein that has almost similar size in SDS-PAGE electrophoresis and is phosphorylated 
(Rima et al. 1981). Our results support this. In addition, it was earlier detected that 
monoclonal antibody bound only to mammalian produced recombinant M and not to the 
bacterial version. It was speculated if the difference is due to phosphorylation in 
mammalian produced protein. Our results confirmed the difference in antibody binding 
not to be because of phosphorylation modification. There are a few differences in the 
protein sequences of the mammalian and E. coli produced proteins which might be big 
enough to prevent the monoclonal antibody from binding to the other. Sequence 
analysis showed that the E. coli produced M protein is similar to Edmonston strain aside 
from T84 to N transition (Appendix 1). There are no equivalent strains in GenBank. The 
mammalian produced strain differs from the E. coli version N84 to T, F276 to L, V308 
to A and V313 to A. There are again no equivalent strains in GenBank with the last 
three substitutions. These changes in protein sequence possibly prevent the monoclonal 
antibodies recognizing the E. coli produced M protein. The phosphorylation hypothesis 
was, however, also supported by a fact that sometimes the M protein seems to run as 
two close bands in SDS-PAGE electrophoresis (Pohl et al. 2007, Liljeroos, L., personal 
communication). The reason for this is unknown. Pohl et al. (2007) hypothesized it not 
59 
 
 
to be because of phosphorylation or polyubiquitination. According to our results the M 
is not phosphorylated, however, the two bands were not seen during these experiments.  
The biological significance of phosphorylation of measles proteins has started to 
unfold and is on a good path to be solved. Right now it seems that phosphorylation 
signalling plays key roles in determining the right stage to transcribe or replicate the 
viral genome during an infection cycle. It would be interesting to know the exact 
difference in RdRp when transcribing or replicating the genome. How it determines 
what to do and when? Perhaps when the RdRp binds RNP, the interaction is stabilized 
by decreasing the phosphorylation of NTAIL and increasing or decreasing the 
phosphorylation of P changes the RdRp somehow to switch between transcription and 
replication. At first the genome is predominantly transcribed and maybe when the pool 
of N0-P –complex in the cytosol rises, the phosphorylation of P decreases as more PNTs 
are preoccupied in N0 binding and the polymerase switches to replication. Since I got 
different results than some of the sources, perhaps the N binding does not change the 
phosphorylation of P and it is changed by something else. In addition, N0-P –complex 
probably prevents the NCORE phosphorylation and it happens only when the N forms 
RNP and stabilizes the structure. Also, it is not known when the M-RNP –complex is 
formed. Whether phosphorylation of N can alter the M-N interaction would be an 
interesting subject of further studies. 
 
6 CONCLUSIONS 
 
The P and N proteins were both produced with six different phosphorylated isoforms 
and one unphosphorylated isoform. The P was more phosphorylated in complex with N 
and the N was more phosphorylated when produced alone. In MV the cytosolic P was 
more phosphorylated than in a released virus, but less than in the recombinant version. 
N was not phosphorylated in a virus. Phosphorylated M protein was not produced.  
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APPENDIX 1: POSSIBLE PHOSPHORYLATION SITES 
 
Possible phosphorylation sites in yellow in used Measles P, N and M 
proteins: 
 
Phosphoprotein – Helsinki strain: 
Met A E E Q A R H V K N G L E C I R A L K A E P I G S L A I E E A Met A A W S 
E I S D N P G Q E R A T C R E E K A G S S G L S K P C L S A I G S T E G G A P R 
I R G Q G P G E S D D D A E T L G I P P R N L Q A S S T G L Q C Y Y V Y D H S 
G E A V K G I Q D A D S I Met V Q S G L D G D S T L S G G D N E S E N S D V D 
I G E P D T E G Y A I T D R G S A P I S Met G F R A S D V E T A E G G E I H E L 
L R L Q S R G N N F P K L G K T L N V P P P P D P G R A S T S G T P I K K G T D 
A R L A S F G T E I A S L L T G G A T Q C A R K S P S E P S G P G A P A G N V P 
E C V S N A A L I Q E W T P E S G T T I S P R S Q N N E E G G D Y Y D D E L F S 
D V Q D I K T A L A K I H E D N Q K I I S K L E S L L L L K G E V E S I K K Q I 
N R Q N I S I S T L E G H L S S I Met I A I P G L G K D P N D P T A D V E I N P D 
L K P I I G R D S G R A L A E V L K K P V A S R Q L Q G Met T N G R T S S R G 
Q L L K E F Q L K P I G K K Met S S A V G F V P D T G P A S R S V I R S I I K S S 
R L E E D R K R Y L Met T L L D D I K G A D D L A K F H Q Met L Met K I I Met 
K Stop 
 
Truncated phosphoprotein1-48 – Helsinki strain: 
Met A E E Q A R H V K N G L E C I R A L K A E P I G S L A I E E A Met A A W S 
E I S D N P G Q E R A Stop 
 
Nucleoprotein – Helsinki strain (same as Halonen strain, GenBank: 
U01996.1): 
Met A T L L R S L A L F K R N K D K P P I T S G S G G A I R G I K H I I I V P I P 
G D S S I T T R S R L L D R L V R L I G N P D V S G P K L T G A L I G I L S L F V 
E S P G Q L I Q R I T D D P D V S I R L L E V V Q S D Q S Q S G L T F A S R G T 
N Met E D E A D Q Y F S H D D P I S S D Q S R F G W F E N K E I S D I E V Q D 
P E G F N Met I L G T I L A Q I W V L L A K A V T A P D T A A D S E L R R W I 
K Y T Q Q R R V V G E F R L E R K W L D V V R N R I A E D L S L R R F Met V 
A L I L D I K R T P G N K P R I A E Met I C D I D T Y I V E A G L A S F I L T I K 
F G I E T Met Y P A L G L H E F A G E L S T L E S L Met N L Y Q Q Met G E T A 
P Y Met V I L E N S I Q N K F S A G S Y P L L W S Y A Met G V G V E L E N S 
Met G G L N F G R S Y F D P A Y F R L G Q E Met V R R S A G K V S S T L A S E 
L G I T A E D A R L V S E I A Met H T T E D K I S R A V G P R Q A Q V S F L H 
G D Q S E N E L P R L G G K E D R R V K Q S R G E A R E S Y R E T G P S R A S 
D A R A A H L P T G T P L D I D T A S E S S Q D P Q D S R R S A D A L L R L Q 
A Met A G I S E E Q G S D T D T P I V Y N D R N L L D Stop 
 
  
70 
 
 
Matrix protein – E. coli produced, codon optimized 
(GenBank: EU332925.1 except for N that is T in Edmonston strain): 
Met T E I Y D F D K S A W D I K G S I A P I Q P T T Y S D G R L V P Q V R V I D 
P G L G D R K D E C F Met Y Met F L L G V V E D S D S L G P P I G R A F G S L 
P L G V G R S N A K P E K L L K E A T E L D I V V R R T A G L N E K L V F Y N 
N T P L T L L T P W R K V L T T G S V F N A N Q V C N A V N L I P L D T P Q R 
F R V V Y Met S I T R L S D N G Y Y T V P R R Met L E F R S V N A V A F N L L 
V T L R I D K A I G P G K I I D N T E Q L P E A T F Met V H I G N F R R K K S E 
V Y S A D Y C K Met K I E K Met G L V F A L G G I G G T S L H I R S T G K Met 
S K T L H A Q L G F K K T L C Y P L Met D I N E D L N R L L W R S R C K I V R 
I Q A V L Q P S V P Q E F R I Y D D V I I N D D Q G L F K V L Stop 
 
Matrix protein – mammalian produced, Helsinki strain 
(Sequence = Differences to E. coli produced version): 
Met T E I Y D F D K S A W D I K G S I A P I Q P T T Y S D G R L V P Q V R V I D 
P G L G D R K D E C F Met Y Met F L L G V V E D S D S L G P P I G R A F G S L 
P L G V G R S T A K P E K L L K E A T E L D I V V R R T A G L N E K L V F Y N 
N T P L T L L T P W R K V L T T G S V F N A N Q V C N A V N L I P L D T P Q R 
F R V V Y Met S I T R L S D N G Y Y T V P R R Met L E F R S V N A V A F N L L 
V T L R I D K A I G P G K I I D N T E Q L P E A T F Met V H I G N F R R K K S E 
V Y S A D Y C K Met K I E K Met G L V F A L G G I G G T S L H I R S T G K Met 
S K T L H A Q L G L K K T L C Y P L Met D I N E D L N R L L W R S R C K I V R 
I Q A A L Q P S A P Q E F R I Y D D V I I N D D Q G L F K V L Stop

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APPENDIX 2: TOOL SITES IN THE ORDER OF USAGE 
 
NEBcutter V2.0 (NEB): 
http://tools.neb.com/NEBcutter2/; visited 11.11.2013. 
 
Double digest finder (NEB): 
http://66.155.211.155/nebecomm/DoubleDigestCalculator.asp; visited 14.11.2013. 
 
Reverse complement tool (The Sequence Manipulation Suite): 
http://www.bioinformatics.org/sms/rev_comp.html; visited 26.11.2013. 
 
Blast (NCBI): 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch
&LINK_LOC=blasthome; visited 26.11.2013. 
 
Translate tool (SIB: ExPASy): 
http://web.expasy.org/translate/; visited 26.11.2013. 
 
LALIGN (SIB: ExPASy): 
http://embnet.vital-it.ch/software/LALIGN_form.html; visited 26.11.2013. 
 
Compute pI/Mw tool (SIB: ExPASy): 
http://web.expasy.org/cgi-bin/compute_pi/pi_tool; visited 26.11.2013. 
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APPENDIX 3: PTT5SH8Q2-PLASMID 
 
 
 
 
  
 
 
Reference: 
https://www4.vanderbilt.edu/vapr/sites/default/files/pTT5SH8Q2plasmid.pdf; visited 
11.11.2013. 
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APPENDIX 4: PCR REACTIONS AND PROGRAMS FOR 
P1-48/PTT5SH8Q2 AND P/PTT5SH8Q2 
 
PCR-reaction mix (50 µl): 
 
31.5 µl MQ 
10    µl 5 x Phusion HF Buffer 
1      µl dNTP mix, final concentration 0.2 mM 
2.5   µl Primer 1 P-Forward-His-NotI, final conc. 0.5 µM   
2.5   µl Primer 2 P1-48-Reverse-EcoRI or P-Reverse-EcoRI, final conc. 0.5 µM 
48.3 ng template P1-48/pET41a or 195 ng template P/pTT5SH8Q2 
1.5   µl DMSO, final conc. 3% (v/v) 
0.5   µl Phusion polymerase   
 
PCR program: 
 
2 cycles   30 s    98°C   
     10 s    98°C    
10 s    59.7°C for P1-48 and 58.4°C for P 
15 s and 45 s 59.7°C for P1-48 and 58.4°C for P 
26 and 25 cycles 10 s    98 °C    
15 s   59.7°C for P1-48 and 58.4°C for P  
Final    5 min   59.7°C for P1-48 and 58.4°C for P 
After the program     stay in 4°C 
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Colony-PCR master mix (198 µl) for the subclones: 
 
132 µl MQ 
40   µl 5 x Phusion HF Buffer 
4     µl dNTP mix, final conc. 0.2 mM 
10   µl Primer 1 P-Forward-His-NotI, final conc. 0.5 µM   
10   µl Primer 2 P1-48-Reverse-EcoRI or P-Reverse-EcoRI, final conc. 0.5 µM 
2     µl Phusion polymerase 
 
Colony-PCR reaction mix (20 µl) for the subclones: 
 
19 µl Master mix 
1   µl template P1-48/pTT5SH8Q2 or P/pTT5SH8Q2 
   
 
PCR program for the colony-PCR: 
 
   30 s    98°C   
2 cycles 10 s    98°C    
10 s    59.7°C for P1-48 and 58.4°C for P 
15 s and 45 s 72°C    
25 cycles 10 s    98 °C    
15 s   72°C    
Final  5 min   72 °C   
After the program   stay in 4°C 
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APPENDIX 5: GEL & RUNNING BUFFER COMPOSITIONS 
 
Phos-tagTM resolving gels: 
 
5% or 7.5% (w/v)  Acrylamide (5% for P and N and 7.5% for M protein) 
6 M    Resolving gel buffer, Tris-HCl, pH 8.8 
50 or 100 µM  Phos-tagTM (50 µM for P and 100 µM for N and M protein)* 
100 or 200 µM   MnCl2 – always double the concentration of Phos-tagTM** 
0.1% (w/v)   Tetramethylethylenediamine (TEMED)  
0.5% (w/v)  Agarose (for P and N protein) 
0.1% (w/v)   Ammonium persulfate (APS) 
in MQ    
 
*Different Phos-tagTM concentrations were tested for optimization: 20, 50 and 100 µM 
were tested for P, 50 and 100 µM for N and M protein.  
 
**Phos-tagTM to MnCl2 ratio of 1:4 was also tested, but it retarded the running of the 
protein samples even more and did not clarify the difference between unphosphorylated 
and phosphorylated isoforms (picture not shown). 
 
Stacking gels for Phos-tagTM gels: 
 
4.5% (w/v)   Acrylamide 
2 M    Stacking gel buffer, Tris-HCl, pH 6.8 
0.1% (w/v)   TEMED 
0.5% (w/v)   Agarose (for N and P) 
0.3% (w/v)   APS 
in MQ    
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SDS-PAGE resolving gels: 
 
7.5% or 10% (w/v) Acrylamide (7.5% for P and 10% for N and M protein) 
6 M    Resolving gel buffer, Tris-HCl, pH 8.8 
0.1% (w/v)   TEMED 
0.1% (w/v)   Sodium dodecyl sulfate (SDS) 
0.1% (w/v)   APS 
in MQ  
 
SDS-PAGE stacking gels: 
 
4.5% (w/v)   Acrylamide 
2 M    Stacking gel buffer, Tris-HCl, pH 6.8 
0.1% (w/v)   TEMED 
0.1% (w/v)   SDS 
0.1% (w/v)   APS 
in MQ    
 
1 × Laemmli buffer (running buffer for gel electrophoresis): 
 
25 mM     Tris, pH 8.3 
192 mM    Glycine 
100 mM   SDS 
in MQ 
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APPENDIX 6: SEQUENCING RESULTS 
 
Sequencing results (quality sequence according the sequencing company 
Integrated DNA Technologies): 
 
Sequence = Restriction enzyme sites (NotI and EcoRI) 
Sequence = Sequenced gene from start codon to stop codon 
Sequence = His-tag 
Sequence = Site were one C is missing from the P subclone 9 
Sequence = Point mutation compared to Edmonston virus AG 
 
Sequencing results of truncated P1-48 subclone 7: 
 
P1-48 subclone 7 Forward primer premixed, bases 17–840 of sequence: 
CTCACAGGTGTCCACTCCCAGGTCCAAGTTTAAACAGCGGCCGCACCATGG
AACATCATCATCATCATCATGCAGAAGAGCAGGCACGCCATGTCAAAAACG
GACTGGAATGCATCCGGGCTCTCAAGGCCGAGCCCATCGGCTCACTGGCCA
TCGAGGAAGCTATGGCAGCATGGTCAGAAATATCAGACAACCCAGGACAG
GAGCGAGCCTAAGAATTCAAGCTTGGGATCCGGTTGGAGCCACCCGCAGTT
CGAGAAAACCGGTCATCATCACCATCACCATCACCATGGAGGACAGTGAAG
ATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAAT
AGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCA
AATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCG
CCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGC
AGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGAACCCTAA
ACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCT
AATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGG
TTAGTAAAAGGGTCCTAAGGAACAGCGATGTATGTGGGCGGGCCAAGATAG
GGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAG
CGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCAC
GGT 
 
Sequencing results of truncated P1-48 subclone 8: 
 
P1-48 subclone 8 Forward primer premixed, bases 16–905 of sequence: 
CTCACAGGTGTCCACTCCCAGGTCCAAGTTTAAACAGCGGCCGCACCATGG
AACATCATCATCATCATCATGCAGAAGAGCAGGCACGCCATGTCAAAAACG
GACTGGAATGCATCCGGGCTCTCAAGGCCGAGCCCATCGGCTCACTGGCCA
TCGAGGAAGCTATGGCAGCATGGTCAGAAATATCAGACAACCCAGGACAG
GAGCGAGCCTAAGAATTCAAGCTTGGGATCCGGTTGGAGCCACCCGCAGTT
CGAGAAAACCGGTCATCATCACCATCACCATCACCATGGAGGACAGTGAAG
ATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAAT
AGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCA
78 
 
 
AATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCG
CCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGC
AGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGAACCCTAA
ACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCT
AATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGG
TTAGTAAAAGGGTCCTAAGGAACAGCGATGTAGGTGGGCGGGCCAAGATA
GGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGA
GCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCA
CGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATA
GCATATGCTATCCTAATCT 
 
Sequencing results of P
 
subclone 8: 
 
P subclone 8 Forward primer premix, bases 13–872 of sequence: 
TCTCACAGGTGTCCACTCCCAGGTCCAAGTTTAAACAGCGGCCGCACCATG
GAACATCATCATCATCATCATGCAGAAGAGCAGGCACGCCATGTCAAAAAC
GGACTGGAATGCATCCGGGCTCTCAAGGCCGAGCCCATCGGCTCACTGGCC
ATCGAGGAAGCTATGGCAGCATGGTCAGAAATATCAGACAACCCAGGACA
GGAGCGAGCCACCTGCAGGGAAGAGAAGGCAGGCAGTTCGGGTCTCAGCA
AACCATGCCTCTCAGCAATTGGATCAACTGAAGGCGGTGCACCTCGCATCC
GCGGTCAGGGACCTGGAGAGAGCGATGACGACGCTGAAACTTTGGGAATCC
CCCCAAGAAATCTCCAGGCATCAAGCACTGGGTTACAGTGTTATTATGTTTA
TGATCACAGCGGTGAAGCGGTTAAGGGAATCCAAGATGCTGACTCTATCAT
GGTTCAATCAGGCCTTGATGGTGATAGCACCCTCTCAGGAGGAGACAATGA
ATCTGAAAACAGCGATGTGGATATTGGCGAACCTGATACCGAGGGATATGC
TATCACTGACCGGGGATCTGCTCCCATCTCTATGGGGTTCAGGGCTTCTGAT
GTTGAAACTGCAGAAGGAGGGGAGATCCACGAGCTCCTGAGACTCCAATCC
AGAGGCAACAACTTTCCGAAGCTTGGGAAAACTCTCAATGTTCCTCCGCCCC
CGGACCCCGGTAGGGCCAGCACTTCCGGGACACCCATTAAAAAGGGCACAG
ACGCGAGATTAGCCTCATTTGGAACGGAGATCGCGTCTTTATTGACAGGTG
GTGCAACCCAATGTGCTCGAAAGTCACCCTCGGAACCATCAGG 
 
P subclone 8 Reverse primer premix, bases 10–843 of sequence: 
GATGACGGTTTTCTCGACTGCGGGTGGCTCCAACCGGATCCCAAGCTTGAAT
TCCTACTTCATTATTATCTTCATCAGCATCTGGTGGAACTTGGCAAGATCAT
CGGCTCCTTTGATATCATCAAGGAGAGTCATCAGGTAACGCTTCCGATCCTC
CTCTAGCCGGCTGGATTTTATAATGGAGCGGATTACACTGCGTGATGCAGG
GCCGGTGTCAGGAACAAACCCGACGGCTGAGCTCATCTTTTTCCCGATCGGC
TTTAGCTGAAATTCCTTCAGCAGCTGTCCTCTGGAACTGGTCCGTCCATTTGT
CATTCCTTGGAGTTGTCGGCTGGCAACGGGTTTCTTGAGAACTTCGGCCAGT
GCTCGGCCTGAATCTCTGCCTATGATGGGTTTCAAGTCGGGATTGATTTCGA
CATCTGCAGTGGGGTCGTTGGGATCCTTCCCAAGTCCAGGAATGGCGATCAT
GATGCTTGAGAGGTGTCCTTCCAGGGTGGATATGCTGATATTTTGCCTGTTG
ATCTGCTTCTTAATTGACTCAACTTCTCCCTTCAATAACAGCAGTGATTCTAG
CTTGGAGATTATCTTCTGATTATCCTCGTGTATTTTGGCCAAGGCTGTTTTAA
TATCTTGGACATCAGAGAACAGCTCATCATCATAATAGTCTCCCCCTTCTTC
ATTATTCTGGGATCTCGGGGAGATTGTGGTACCAGATTCGGGTGTCCACTCC
TGTATCAGTGCGGCATTGCTCACACACTCGGGGACATTCCCCGCAGGTGCAC
CTGGCCCTGATGGTTCCGAGGGTGACTTTCGAGCACATTGGGTTGCACCACC 
79 
 
 
Reverse complement of P subclone 8 Reverse primer premix, bases 10–843 of 
sequence: 
GGTGGTGCAACCCAATGTGCTCGAAAGTCACCCTCGGAACCATCAGGGCCA
GGTGCACCTGCGGGGAATGTCCCCGAGTGTGTGAGCAATGCCGCACTGATA
CAGGAGTGGACACCCGAATCTGGTACCACAATCTCCCCGAGATCCCAGAAT
AATGAAGAAGGGGGAGACTATTATGATGATGAGCTGTTCTCTGATGTCCAA
GATATTAAAACAGCCTTGGCCAAAATACACGAGGATAATCAGAAGATAATC
TCCAAGCTAGAATCACTGCTGTTATTGAAGGGAGAAGTTGAGTCAATTAAG
AAGCAGATCAACAGGCAAAATATCAGCATATCCACCCTGGAAGGACACCTC
TCAAGCATCATGATCGCCATTCCTGGACTTGGGAAGGATCCCAACGACCCC
ACTGCAGATGTCGAAATCAATCCCGACTTGAAACCCATCATAGGCAGAGAT
TCAGGCCGAGCACTGGCCGAAGTTCTCAAGAAACCCGTTGCCAGCCGACAA
CTCCAAGGAATGACAAATGGACGGACCAGTTCCAGAGGACAGCTGCTGAAG
GAATTTCAGCTAAAGCCGATCGGGAAAAAGATGAGCTCAGCCGTCGGGTTT
GTTCCTGACACCGGCCCTGCATCACGCAGTGTAATCCGCTCCATTATAAAAT
CCAGCCGGCTAGAGGAGGATCGGAAGCGTTACCTGATGACTCTCCTTGATG
ATATCAAAGGAGCCGATGATCTTGCCAAGTTCCACCAGATGCTGATGAAGA
TAATAATGAAGTAGGAATTCAAGCTTGGGATCCGGTTGGAGCCACCCGCAG
TCGAGAAAACCGTCATC 
 
Sequencing results of P
 
subclone 9: 
 
P subclone 9 Forward primer premix, bases 16–809 of sequence: 
CTCACAGGTGTCCACTCCCAGGTCCAAGTTTAAACAGCGGCCGCACCATGG
AACATCATCATCATCATCATGCAGAAGAGCAGGCACGCCATGTCAAAAACG
GACTGGAATGCATCCGGGCTCTCAAGGCCGAGCCCATCGGCTCACTGGCCA
TCGAGGAAGCTATGGCAGCATGGTCAGAAATATCAGACAACCCAGGACAG
GAGCGAGCCACCTGCAGGGAAGAGAAGGCAGGCAGTTCGGGTCTCAGCAA
ACCATGCCTCTCAGCAATTGGATCAACTGAAGGCGGTGCACCTCGCATCCG
CGGTCAGGGACCTGGAGAGAGCGATGACGACGCTGAAACTTTGGGAATCCC
CCCAAGAAATCTCCAGGCATCAAGCACTGGGTTACAGTGTTATTATGTTTAT
GATCACAGCGGTGAAGCGGTTAAGGGAATCCAAGATGCTGACTCTATCATG
GTTCAATCAGGCCTTGATGGTGATAGCACCCTCTCAGGAGGAGACAATGAA
TCTGAAAACAGCGATGTGGATATTGGCGAACCTGATACCGAGGGATATGCT
ATCACTGACCGGGGATCTGCTCCCATCTCTATGGGGTTCAGGGCTTCTGATG
TTGAAACTGCAGAAGGAGGGGAGATCCACGAGCTCCTGAGACTCCAATCCA
GAGGCAACAACTTTCCGAAGCTTGGGAAAACTCTCAATGTTCCTCCGCCCCC
GGACCCCGGTAGGGCCAGCACTTCCGGGACACCCATTAAAAAGGGCACAGA
CGCGAGATTAGCCTCATTTGGAACGGAG 
 
P subclone 9 Reverse primer premix, bases 26–799 of sequence: 
CGGTTTCTCGACTGCGGGTGGCTCCAACCGGATCCCAAGCTTGAATTCCTAC
TTCATTATTATCTTCATCAGCATCTGGTGGAACTTGGCAAGATCATCGGCTC
CTTTGATATCATCAAGGAGAGTCATCAGGTAACGCTTCCGATCCTCCTCTAG
CCGGCTGGATTTTATAATGGAGCGGATTACACTGCGTGATGCAGGGCCGGT
GTCAGGAACAAACCCGACGGCTGAGCTCATCTTTTTCCCGATCGGCTTTAGC
TGAAATTCCTTCAGCAGCTGTCCTCTGGAACTGGTCCGTCCATTTGTCATTCC
TTGGAGTTGTCGGCTGGCAACGGGTTTCTTGAGAACTTCGGCCAGTGCTCGG
80 
 
 
CCTGAATCTCTGCCTATGATGGGTTTCAAGTCGGGATTGATTTCGACATCTG
CAGTGGGGTCGTTGGGATCCTTCCCAAGTCCAGGAATGGCGATCATGATGC
TTGAGAGGTGTCCTTCCAGGGTGGATATGCTGATATTTTGCCTGTTGATCTG
CTTCTTAATTGACTCAACTTCTCCCTTCAATAACAGCAGTGATTCTAGCTTGG
AGATTATCTTCTGATTATCCTCGTGTATTTTGGCCAAGGCTGTTTTAATATCT
TGGACATCAGAGAACAGCTCATCATCATAATAGTCTCCCCCTTCTTCATTAT
TCTGGGATCTCGGGGAGATTGTGGTACCAGATTCGGGTGTCCACTCCTGTAT
CAGTGCGGCATTGCTCACACACTCGGGGACATTCCCCGCAGTGCA 
 
Reverse complement of P subclone 9 Reverse primer premix, bases 26–799 of 
sequence: 
TGCACTGCGGGGAATGTCCCCGAGTGTGTGAGCAATGCCGCACTGATACAG
GAGTGGACACCCGAATCTGGTACCACAATCTCCCCGAGATCCCAGAATAAT
GAAGAAGGGGGAGACTATTATGATGATGAGCTGTTCTCTGATGTCCAAGAT
ATTAAAACAGCCTTGGCCAAAATACACGAGGATAATCAGAAGATAATCTCC
AAGCTAGAATCACTGCTGTTATTGAAGGGAGAAGTTGAGTCAATTAAGAAG
CAGATCAACAGGCAAAATATCAGCATATCCACCCTGGAAGGACACCTCTCA
AGCATCATGATCGCCATTCCTGGACTTGGGAAGGATCCCAACGACCCCACT
GCAGATGTCGAAATCAATCCCGACTTGAAACCCATCATAGGCAGAGATTCA
GGCCGAGCACTGGCCGAAGTTCTCAAGAAACCCGTTGCCAGCCGACAACTC
CAAGGAATGACAAATGGACGGACCAGTTCCAGAGGACAGCTGCTGAAGGA
ATTTCAGCTAAAGCCGATCGGGAAAAAGATGAGCTCAGCCGTCGGGTTTGT
TCCTGACACCGGCCCTGCATCACGCAGTGTAATCCGCTCCATTATAAAATCC
AGCCGGCTAGAGGAGGATCGGAAGCGTTACCTGATGACTCTCCTTGATGAT
ATCAAAGGAGCCGATGATCTTGCCAAGTTCCACCAGATGCTGATGAAGATA
ATAATGAAGTAGGAATTCAAGCTTGGGATCCGGTTGGAGCCACCCGCAGTC
GAGAAACCG 
 
 
